<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Vepdegestrant (ARV-471) - Complete Investment Analysis | Leaf Intelligence</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
            background: #f8f9fa;
            color: #333;
            font-size: 14px;
            line-height: 1.5;
        }

        .nav-bar {
            background: white;
            height: 56px;
            display: flex;
            align-items: center;
            padding: 0 24px;
            position: fixed;
            top: 0;
            left: 0;
            right: 0;
            z-index: 1000;
            box-shadow: 0 1px 3px rgba(0,0,0,0.08);
        }

        .container {
            margin-top: 56px;
            padding: 32px 24px;
            max-width: 1400px;
            margin-left: auto;
            margin-right: auto;
        }

        .tab-container {
            background: white;
            border-radius: 12px;
            box-shadow: 0 2px 8px rgba(0,0,0,0.06);
            overflow: hidden;
            margin-top: 24px;
        }

        .tabs {
            display: flex;
            border-bottom: 2px solid #e3f2f0;
            overflow-x: auto;
            background: #fafffe;
        }

        .tab-btn {
            padding: 14px 20px;
            border: none;
            background: none;
            color: #6c757d;
            font-size: 13px;
            font-weight: 600;
            cursor: pointer;
            white-space: nowrap;
            border-bottom: 3px solid transparent;
            transition: all 0.2s;
        }

        .tab-btn:hover {
            color: #0a6b5e;
            background: #f0f7f6;
        }

        .tab-btn.active {
            color: #0a6b5e;
            border-bottom-color: #0a6b5e;
            background: white;
        }

        .tab-content {
            padding: 24px;
            display: none;
        }

        .tab-content.active {
            display: block;
        }

        .section-title {
            font-size: 20px;
            font-weight: 600;
            color: #0a6b5e;
            margin-bottom: 16px;
        }

        .subsection-title {
            font-size: 16px;
            font-weight: 600;
            color: #333;
            margin-top: 20px;
            margin-bottom: 12px;
        }

        .data-card {
            background: #f8fffe;
            border: 1px solid #e3f2f0;
            border-radius: 8px;
            padding: 16px;
            margin-bottom: 16px;
        }

        .detail-text {
            color: #424242;
            line-height: 1.6;
            margin-bottom: 12px;
        }

        .metric-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(250px, 1fr));
            gap: 16px;
            margin-top: 16px;
        }

        .metric-card {
            background: white;
            border: 1px solid #e3f2f0;
            border-radius: 8px;
            padding: 16px;
        }

        .metric-label {
            font-size: 12px;
            color: #6c757d;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            margin-bottom: 8px;
        }

        .metric-value {
            font-size: 24px;
            font-weight: 600;
            color: #0a6b5e;
        }

        .metric-detail {
            font-size: 12px;
            color: #6c757d;
            margin-top: 4px;
        }

        .expandable-section {
            border: 1px solid #e3f2f0;
            border-radius: 8px;
            margin-bottom: 12px;
            overflow: hidden;
        }

        .expandable-header {
            background: #f0f7f6;
            padding: 12px 16px;
            cursor: pointer;
            display: flex;
            justify-content: space-between;
            align-items: center;
            font-weight: 600;
            color: #0a6b5e;
            transition: background 0.2s;
        }

        .expandable-header:hover {
            background: #e6f3f1;
        }

        .expandable-content {
            padding: 16px;
            display: none;
            background: white;
        }

        .expandable-content.active {
            display: block;
        }

        .timeline-container {
            position: relative;
            padding-left: 40px;
            margin: 20px 0;
        }

        .timeline-line {
            position: absolute;
            left: 12px;
            top: 24px;
            bottom: 24px;
            width: 2px;
            background: #e3f2f0;
        }

        .timeline-item {
            position: relative;
            margin-bottom: 24px;
        }

        .timeline-dot {
            position: absolute;
            left: -32px;
            top: 4px;
            width: 12px;
            height: 12px;
            background: #0a6b5e;
            border: 3px solid white;
            border-radius: 50%;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
        }

        .timeline-date {
            font-size: 12px;
            color: #6c757d;
            font-weight: 600;
            margin-bottom: 4px;
        }

        .timeline-content {
            background: white;
            border: 1px solid #e3f2f0;
            border-radius: 8px;
            padding: 12px;
        }

        .trial-table {
            width: 100%;
            border-collapse: collapse;
            margin-top: 16px;
        }

        .trial-table th {
            background: #f0f7f6;
            padding: 12px;
            text-align: left;
            font-size: 12px;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            color: #0a6b5e;
            border-bottom: 2px solid #e3f2f0;
        }

        .trial-table td {
            padding: 12px;
            border-bottom: 1px solid #f0f7f6;
            font-size: 13px;
            vertical-align: top;
        }

        .status-badge {
            display: inline-block;
            padding: 4px 10px;
            border-radius: 6px;
            font-size: 11px;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.3px;
        }

        .status-active { 
            background: #d4f4ec;
            color: #0a6b5e;
        }

        .status-completed { 
            background: #e3f2f0;
            color: #0a6b5e;
        }

        .status-recruiting { 
            background: #cfe2ff;
            color: #084298;
        }

        .link-btn {
            color: #0a6b5e;
            text-decoration: none;
            font-size: 12px;
            font-weight: 600;
            display: inline-flex;
            align-items: center;
            gap: 4px;
            padding: 4px 8px;
            border-radius: 4px;
            transition: all 0.2s;
        }

        .link-btn:hover {
            background: #f0f7f6;
        }

        .ae-table {
            width: 100%;
            margin-top: 16px;
        }

        .ae-table th {
            background: #fff3cd;
            padding: 10px;
            text-align: left;
            font-size: 12px;
            font-weight: 600;
            color: #856404;
        }

        .ae-table td {
            padding: 10px;
            border-bottom: 1px solid #fff3cd;
            font-size: 13px;
        }

        .reference-list {
            font-size: 11px;
            color: #6c757d;
            margin-top: 8px;
            padding-top: 8px;
            border-top: 1px solid #e3f2f0;
        }

        .chart-container {
            position: relative;
            height: 300px;
            margin: 20px 0;
        }

        .regulatory-flow {
            display: flex;
            align-items: center;
            gap: 20px;
            margin: 20px 0;
            overflow-x: auto;
            padding: 20px 0;
        }

        .flow-node {
            background: white;
            border: 2px solid #0a6b5e;
            border-radius: 8px;
            padding: 16px;
            min-width: 200px;
            text-align: center;
            position: relative;
        }

        .flow-node.completed {
            background: #d4f4ec;
        }

        .flow-node.active {
            background: #cfe2ff;
            border-color: #084298;
        }

        .flow-arrow {
            position: absolute;
            right: -25px;
            top: 50%;
            transform: translateY(-50%);
            color: #0a6b5e;
            font-size: 20px;
        }

        .highlight-box {
            background: linear-gradient(135deg, #f0f7f6 0%, #e6f3f1 100%);
            border-left: 4px solid #0a6b5e;
            padding: 16px;
            margin: 16px 0;
            border-radius: 0 8px 8px 0;
        }

        .risk-item {
            display: flex;
            align-items: flex-start;
            margin-bottom: 12px;
        }

        .risk-indicator {
            width: 8px;
            height: 8px;
            border-radius: 50%;
            margin-right: 12px;
            margin-top: 6px;
            flex-shrink: 0;
        }

        .risk-high { background: #dc3545; }
        .risk-medium { background: #ffc107; }
        .risk-low { background: #28a745; }
    </style>
</head>
<body>
    <!-- Navigation -->
    <nav class="nav-bar">
        <div class="flex items-center space-x-3">
            <div class="flex items-center">
                <img src="leaf.png" alt="Leaf Intelligence" class="h-14 w-14 object-contain">
                <div class="ml-3">
                    <span class="text-xl font-bold bg-gradient-to-r from-emerald-600 via-blue-600 to-purple-600 bg-clip-text text-transparent">
                        Leaf Intelligence
                    </span>
                    <div class="text-xs text-gray-600 font-medium tracking-wide">AI Research Platform</div>
                </div>
            </div>
        </div>
        <div class="nav-tabs ml-8">
            <a href="#" class="nav-tab">Companies</a>
            <a href="#" class="nav-tab active">Pharmaceuticals Intelligence</a>
            <a href="#" class="nav-tab">Reports</a>
        </div>
    </nav>

    <!-- Main Content -->
    <div class="container">
        <!-- Header -->
        <div class="bg-white rounded-lg p-6 shadow-sm mb-6">
            <div class="flex justify-between items-start">
                <div>
                    <h1 class="text-3xl font-bold text-gray-900">Vepdegestrant (ARV-471)</h1>
                    <p class="text-lg text-gray-600 mt-2">First-in-Class Oral PROTAC Estrogen Receptor Degrader</p>
                    <div class="flex gap-4 mt-4">
                        <span class="status-badge status-active">Phase 3</span>
                        <span class="text-sm text-gray-600">Pfizer / Arvinas Partnership</span>
                        <span class="text-sm text-gray-600">Target: ER+/HER2- Breast Cancer with ESR1 Mutations</span>
                    </div>
                </div>
                <div class="text-right">
                    <div class="text-sm text-gray-500">Regulatory Status</div>
                    <div class="text-2xl font-bold text-green-600">NDA Accepted</div>
                    <div class="text-sm text-gray-500">FDA Fast Track • Priority Review</div>
                    <div class="text-sm text-gray-500">PDUFA: Q1 2026</div>
                </div>
            </div>
        </div>

        <!-- Tab Container -->
        <div class="tab-container">
            <div class="tabs">
                                <button class="tab-btn active" onclick="showTab('Overview')">Overview</button>
                <button class="tab-btn" onclick="showTab('clinical')">Clinical & Regulatory</button>
                <button class="tab-btn" onclick="showTab('scientific')">Scientific & IP</button>
                <button class="tab-btn" onclick="showTab('commercial')">Commercial & Market</button>
                <button class="tab-btn" onclick="showTab('financial')">Financial & Strategic</button>
                <button class="tab-btn" onclick="showTab('operational')">Operational & Legal</button>
                <button class="tab-btn" onclick="showTab('management')">Management & Team</button>
                <button class="tab-btn" onclick="showTab('safety')">Safety & Toxicology</button>
                <button class="tab-btn" onclick="showTab('trials')">Complete Trial Analysis</button>
            </div>


            <!-- Overview Tab Content -->
<div id="Overview" class="tab-content active">
    <div class="section-title">Executive Overview: Complete Investment Intelligence Analysis</div>
    
    <!-- Key Points Summary -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>Key Investment Points & PTRS Assessment</span>
            <span>▼</span>
        </div>
        <div class="expandable-content active">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">Investment Thesis Summary</h4>
                <p class="detail-text">
                    Research suggests Vepdegestrant (ARV-471) has a high likelihood of FDA approval for ESR1-mutant ER+/HER2- advanced breast cancer in the second-line setting, based on positive Phase 3 data showing improved progression-free survival over fulvestrant, though outcomes in the broader population were less definitive.
                </p>
            </div>

            <div class="metric-grid mt-4">
                <div class="metric-card">
                    <div class="metric-label">PTRS Score</div>
                    <div class="metric-value">80-90%</div>
                    <div class="metric-detail">ESR1-mutant approval likelihood</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Technical Success</div>
                    <div class="metric-value">~95%</div>
                    <div class="metric-detail">Efficacy met in Phase 3</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Regulatory Success</div>
                    <div class="metric-value">~85%</div>
                    <div class="metric-detail">Biomarker gating risks</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Cash Runway</div>
                    <div class="metric-value">2H 2028</div>
                    <div class="metric-detail">$861M cash position</div>
                </div>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Critical Success Factors</h4>
                <ul class="space-y-2">
                    <li>• Evidence leans toward Vepdegestrant being positioned primarily for second-line therapy post-endocrine treatment, with potential expansion to first-line if ongoing trials succeed, though controversy exists around its efficacy in non-mutant subgroups</li>
                    <li>• Competitive landscape includes several oral SERDs, with some China-origin programs like SCR-6852 showing promise in early trials, potentially undercutting costs but facing inflation risks in data</li>
                    <li>• Geographic biases in AE reporting, such as under-reporting in China due to cultural factors, could affect trial interpretations, though Vepdegestrant's global trials include mitigation strategies like diverse sites</li>
                    <li>• Pfizer's partnership provides strong financing, with Arvinas' cash runway extending to 2028, supporting Phase 3 costs estimated in hundreds of millions, though thresholds for progression appear aligned between partners</li>
                    <li>• Operational disclosures on CT.gov appear consistent, with protocol updates reflecting data from investigator brochures, and no major gaps noted</li>
                    <li>• Overall PTRS is estimated high (around 80-90%) for ESR1-mutant approval, with analyst tools suggesting strong regulatory success post-Phase 3, though SME adjustments may account for competitor dynamics</li>
                </ul>
            </div>
        </div>
    </div>

    <!-- 1. Regulatory Guidance & Interactions -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>1. Regulatory Guidance & Interactions - Trial Shaping Analysis</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">FDA/EMA Regulatory Shaping</h4>
                <p class="detail-text">
                    It seems likely that regulatory guidance emphasized PFS as the primary endpoint and fulvestrant as the control arm, aligning with precedents for oral SERDs like elacestrant. Regulatory interactions have played a pivotal role in shaping Vepdegestrant's development, particularly in trial design elements like control arms, endpoints, and labeling pathways.
                </p>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Key Regulatory Milestones & Guidance</h4>
                <p class="detail-text">
                    The FDA granted Fast Track designation in February 2024 for monotherapy in ER+/HER2- metastatic breast cancer post-endocrine therapy, facilitating frequent interactions to expedite development. While specific meeting dates (e.g., pre-IND, End-of-Phase 2) are not publicly detailed, the program's alignment with FDA oncology endpoint guidance—emphasizing PFS as a surrogate for overall survival (OS) in advanced settings—suggests regulator input.
                </p>
                
                <p class="detail-text mt-2">
                    For VERITAC-2 (NCT05654623), the control arm of fulvestrant (standard SERD) and primary endpoint of PFS in ESR1-mutant subgroup (with overall population as secondary) likely reflect FDA recommendations, mirroring the EMERALD trial for elacestrant, which secured approval in a similar biomarker-defined population. No Special Protocol Assessment (SPA) is mentioned, but the stratified design by ESR1 status indicates guidance to address mutant-driven resistance.
                </p>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Label Trajectory & Implications</h4>
                <p class="detail-text">
                    Sponsors followed this closely, as evidenced by the NDA submission focusing on ESR1-mutants where PFS benefit was clear (HR 0.57, P<0.001), while diverging slightly in broader claims pending OS maturity. For EMA, similar PFS focus is expected, with potential conditional approval if OS trends positive.
                </p>
                
                <p class="detail-text mt-2">
                    In China (NMPA/PMDA), a Phase 1b bridging study (NCT05732428) confirmed PK/safety comparability, supporting inclusion in global trials and local registration without major divergence. Label implications point to accelerated approval for 2L monotherapy in mutants, with full approval contingent on OS; combo-only or broader use may require VERITAC-3 data.
                </p>

                <p class="detail-text mt-2">
                    Safety asks appear minimal, given the favorable profile (low grade 3/4 AEs ~23%). Updates post-interim results or competitor events (e.g., imlunestrant discontinuation) likely refined the path.
                </p>
            </div>

            <div class="reference-list">
                Sources: <a href="https://www.pfizer.com/news/announcements/arvinas-and-pfizers-vepdegestrant-arv-471-receives-fda-fast-track-designation" target="_blank" class="link-btn">FDA Fast Track Announcement</a> | 
                <a href="https://www.fda.gov/media/71195/download" target="_blank" class="link-btn">FDA Oncology Endpoint Guidance</a> |
                <a href="https://www.clinicaltrials.gov/study/NCT05654623" target="_blank" class="link-btn">VERITAC-2 Trial</a>
            </div>
        </div>
    </div>

    <!-- 2. Standard of Care Dossier -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>2. Standard of Care (SoC) Comprehensive Dossier</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">Current Treatment Landscape Analysis</h4>
                <p class="detail-text">
                    The standard of care for ER+/HER2- metastatic breast cancer varies by region and line, with CDK4/6 inhibitors plus endocrine therapy often favored first-line in the US and EU, but chemotherapy more common in China; weaknesses include resistance development and variable OS benefits.
                </p>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">US/EU Standard of Care by Line</h4>
                <p class="detail-text">
                    The SoC for ER+/HER2- metastatic breast cancer is endocrine therapy (ET)-based, evolving with CDK4/6 inhibitors and targeted agents, but remains "squishy" in later lines due to resistance and variable global access.
                </p>
                
                <p class="detail-text mt-2">
                    <strong>First-Line (1L):</strong> In the US/EU (FDA/EMA-approved), first-line typically involves CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) + aromatase inhibitors (AIs like letrozole) or fulvestrant, with PFS ~24-28 months and OS benefits (e.g., ribociclib + letrozole: median OS 63.9 months in MONALEESA-2). Efficacy metrics: ORR 40-50%, PFS 20-25 months; safety includes neutropenia (60-70% grade 3/4 for palbociclib), fatigue, but manageable.
                </p>

                <p class="detail-text mt-2">
                    <strong>Weaknesses:</strong> ESR1 mutations emerge in 30-40% post-CDK4/6, reducing ET efficacy; open-label trials may bias PROs; no OS in all subgroups (e.g., visceral disease).
                </p>

                <p class="detail-text mt-2">
                    <strong>Second-Line (2L):</strong> Second-line shifts to fulvestrant monotherapy (PFS ~7 months, ORR ~20%) or everolimus + exemestane (PFS ~7-11 months), with weaknesses like injection-site reactions for fulvestrant and stomatitis for everolimus.
                </p>

                <p class="detail-text mt-2">
                    <strong>Third-Line (3L+):</strong> Third-line often chemo (capecitabine, PFS ~4-6 months), with high toxicity (myelosuppression).
                </p>
            </div>

            <table class="trial-table mt-4">
                <thead>
                    <tr>
                        <th>Line of Therapy</th>
                        <th>US/EU Regimens</th>
                        <th>Efficacy (ORR/PFS/OS)</th>
                        <th>Safety (Common AEs)</th>
                        <th>Weaknesses</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>1L</td>
                        <td>CDK4/6i + AI/fulvestrant</td>
                        <td>ORR 40-55%, PFS 20-28 mo, OS 50-65 mo</td>
                        <td>Neutropenia (50-70%), fatigue (30-40%)</td>
                        <td>Resistance (ESR1 mut 30-40%), no OS in all</td>
                    </tr>
                    <tr>
                        <td>2L</td>
                        <td>Fulvestrant mono or + everolimus/PI3Ki</td>
                        <td>ORR 15-25%, PFS 5-11 mo, OS 20-30 mo</td>
                        <td>Injection reactions (20%), stomatitis (40%)</td>
                        <td>Squishy post-CDK4/6, open-label bias</td>
                    </tr>
                    <tr>
                        <td>3L+</td>
                        <td>Chemo (capecitabine, eribulin)</td>
                        <td>ORR 10-20%, PFS 3-6 mo, OS 12-18 mo</td>
                        <td>Myelosuppression (50%), neuropathy (30%)</td>
                        <td>High toxicity, lack of targeted options</td>
                    </tr>
                    <tr>
                        <td>China/Japan Variant</td>
                        <td>Chemo + ET more common 1L/2L</td>
                        <td>Similar PFS/OS but lower access to CDK4/6</td>
                        <td>Comparable, but under-reported AEs</td>
                        <td>Cost barriers, inflated PROs culturally</td>
                    </tr>
                </tbody>
            </table>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Regional Variations & Challenges</h4>
                <p class="detail-text">
                    In China/Japan, chemo is more frequent even 1L (due to cost/access), with regimens like taxanes + ET; NMPA-approved CDK4/6 use lags, efficacy similar but OS lower (~40-50 months overall) from landmark trials like BOLERO-2.
                </p>
                
                <p class="detail-text mt-2">
                    Weaknesses globally: poorly defined post-CDK4/6 SoC pushes approvals to later lines; small effect sizes in mutants; cultural biases in AE reporting (e.g., under-reporting in Asia). Vepdegestrant's VERITAC-2 positions it against fulvestrant in 2L, potentially elevating SoC if approved, but requires clear mutant benefit to justify earlier use.
                </p>
            </div>

            <div class="reference-list">
                Sources: <a href="https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-023-03238-2" target="_blank" class="link-btn">BMC Medicine Analysis</a> | 
                <a href="https://link.springer.com/article/10.1007/s10549-022-06709-x" target="_blank" class="link-btn">Breast Cancer Research</a> |
                <a href="https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21777" target="_blank" class="link-btn">CA Cancer Journal</a>
            </div>
        </div>
    </div>

    <!-- 3. PTRS Analysis -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>3. Probability of Technical & Regulatory Success (PTRS) - Quantitative Analysis</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">AI-Derived & SME-Adjusted PTRS Assessment</h4>
                <p class="detail-text">
                    PTRS for Vepdegestrant integrates biology (PROTAC ER degradation effective in mutants), precedents (elacestrant approval), trial design (powered for PFS in mutants), and regulatory climate favoring oral SERDs.
                </p>
            </div>

            <div class="metric-grid mt-4">
                <div class="metric-card">
                    <div class="metric-label">Pre-Phase 3 LoA</div>
                    <div class="metric-value">70-80%</div>
                    <div class="metric-detail">GlobalData AI estimate</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Post-VERITAC-2 LoA</div>
                    <div class="metric-value">85-95%</div>
                    <div class="metric-detail">After positive data</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">ESR1-mut Approval</div>
                    <div class="metric-value">90%</div>
                    <div class="metric-detail">Analyst consensus 2026</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Technical Score</div>
                    <div class="metric-value">~95%</div>
                    <div class="metric-detail">Efficacy endpoints met</div>
                </div>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">PTRS Adjustment Factors</h4>
                <p class="detail-text">
                    AI-derived estimates from GlobalData place LoA at ~70-80% pre-Phase 3, rising to 85-95% post-VERITAC-2 success. SME overlays adjust upward for clean safety (low discontinuations ~3%) but downward for non-significant overall PFS (HR 0.83), potentially limiting label breadth.
                </p>
                
                <p class="detail-text mt-2">
                    <strong>Positive Inputs:</strong> Mechanism precedents (PROTACs novel but validated in Phase 1/2 CBR 40%); endpoint choices (PFS surrogate accepted); climate (FDA Fast Track signals high unmet need).
                </p>

                <p class="detail-text mt-2">
                    <strong>Updates & Adjustments:</strong> Updates post-interim (e.g., VERITAC-3 enrollment) or competitors (Lilly discontinuation) boost PTRS ~10%. Analyst consensus: 90% for ESR1-mut approval by 2026, with rationale for SME up-adjust due to tolerability edge over injectables.
                </p>

                <p class="detail-text mt-2">
                    <strong>Quantitative Scoring:</strong> Technical ~95% (efficacy met), Regulatory ~85% (biomarker gating risks).
                </p>
            </div>

            <div class="reference-list">
                Sources: <a href="https://www.pharmaceutical-technology.com/data-insights/vepdegestrant-arvinas-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/" target="_blank" class="link-btn">GlobalData PTRS Analysis</a>
            </div>
        </div>
    </div>

    <!-- 4. Drug Overview (from original text) -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>4. Comprehensive Drug Profile & Development History</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">Vepdegestrant Overview</h4>
                <p class="detail-text">
                    Vepdegestrant is an oral PROTAC ER degrader developed by Arvinas and Pfizer, targeting ER+/HER2- metastatic breast cancer, particularly in ESR1-mutant cases. It degrades the estrogen receptor more effectively than traditional SERDs like fulvestrant, offering oral convenience and potential for overcoming resistance.
                </p>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Development Timeline & Key Results</h4>
                <p class="detail-text">
                    Vepdegestrant (ARV-471) represents a promising advancement in endocrine therapy for ER+/HER2- metastatic breast cancer, leveraging PROTAC technology to achieve potent ER degradation, including in ESR1-mutant tumors that drive resistance to standard treatments. Developed through a collaboration between Arvinas and Pfizer since 2021, the program has progressed rapidly from early-phase trials showing encouraging clinical benefit rates (CBRs) in refractory patients to Phase 3 data demonstrating progression-free survival (PFS) improvements over fulvestrant in key subgroups.
                </p>

                <p class="detail-text mt-2">
                    Phase 3 VERITAC-2 data showed PFS benefits in mutants (5.0 vs 2.1 months, HR 0.57), but not overall (HR 0.83, non-significant). An NDA was accepted by FDA in August 2025 with priority review.
                </p>

                <p class="detail-text mt-2">
                    As of August 2025, the FDA has accepted the New Drug Application (NDA) for vepdegestrant as monotherapy in ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer post-prior endocrine therapy, with a PDUFA date of June 5, 2026, and Fast Track designation underscoring its potential.
                </p>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Trial Design and Outcomes</h4>
                <p class="detail-text">
                    Early phases (Phase 1/2) in heavily pretreated patients yielded a 40% CBR, with better results in ESR1-mutants (~50%). Safety was favorable, with mostly grade 1-2 AEs like nausea and fatigue, no DLTs up to 700 mg.
                </p>

                <p class="detail-text mt-2">
                    VERITAC-3 tests first-line combo with palbociclib vs letrozole + palbociclib, ongoing with sites including China. A China bridging study confirmed similar PK and safety, supporting global inclusion.
                </p>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Regulatory Outlook</h4>
                <p class="detail-text">
                    Fast Track designation highlights unmet need, with NDA based on VERITAC-2. Approval could come by mid-2026, likely limited to ESR1-mutants initially, with companion diagnostics required.
                </p>
            </div>

            <div class="reference-list">
                Sources: <a href="https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-fda-acceptance-new-drug-application" target="_blank" class="link-btn">NDA Acceptance</a> | 
                <a href="https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizers-vepdegestrant-significantly-improves" target="_blank" class="link-btn">Phase 3 Results</a>
            </div>
        </div>
    </div>

    <!-- 5. Competitive Intelligence -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>5. Competitive Intelligence - Focus on China-Origin Programs</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">Competitive Landscape Analysis</h4>
                <p class="detail-text">
                    The oral SERD space is crowded, with ~10 assets in development, but Vepdegestrant's PROTAC edge (89% ER degradation) positions it strongly. Vepdegestrant's PROTAC mechanism may offer advantages in degradation efficiency.
                </p>
            </div>

            <table class="trial-table mt-4">
                <thead>
                    <tr>
                        <th>Competitor</th>
                        <th>Mechanism/Phase/Geography</th>
                        <th>Trial Design/Key Data</th>
                        <th>Funding/Licensing</th>
                        <th>Inflation Risk</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Elacestrant</td>
                        <td>SERD/Approved/US-EU</td>
                        <td>EMERALD: PFS HR 0.55 mutants</td>
                        <td>Menarini global license</td>
                        <td>Low (global data)</td>
                    </tr>
                    <tr>
                        <td>SCR-6852</td>
                        <td>SERD/Phase 1/China</td>
                        <td>Single-arm, brain-pen: Preclin PFS > fulvestrant</td>
                        <td>Simcere internal</td>
                        <td>High (China-only)</td>
                    </tr>
                    <tr>
                        <td>LX-039</td>
                        <td>SERD/Phase 1-2/China-US</td>
                        <td>Mono: CBR ~40% pretreated</td>
                        <td>InventisBio + global out-license</td>
                        <td>Medium (bridging planned)</td>
                    </tr>
                    <tr>
                        <td>Giredestrant</td>
                        <td>SERD/Phase 3/Global</td>
                        <td>acelERA: PFS HR 0.81</td>
                        <td>Roche self-funded</td>
                        <td>Low</td>
                    </tr>
                    <tr>
                        <td>Camizestrant</td>
                        <td>SERD/Phase 3/Global</td>
                        <td>Phase 2: ~6.3 vs 2.2 mo ESR1-mut</td>
                        <td>AstraZeneca</td>
                        <td>Low</td>
                    </tr>
                </tbody>
            </table>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Key Competitors Deep Dive</h4>
                <p class="detail-text">
                    <strong>Elacestrant (approved 2023):</strong> For ESR1-mut 2L, PFS HR 0.55 but GI toxicity high (35% nausea rate); giredestrant (Roche, Phase 3, brain-penetrant but mixed Phase 2); camizestrant (AstraZeneca, Phase 3, potent but bradycardia risks).
                </p>

                <p class="detail-text mt-2">
                    <strong>China-origin programs:</strong> SCR-6852 (Simcere, Phase 1, high brain penetration, preclinical PFS superior in mutants, funding via internal + partnerships, planning US bridging); LX-039 (InventisBio, Phase 1/2, robust antitumor in ER+ models, licensed to global pharma for ex-China rights, inflation risk in China-only data).
                </p>

                <p class="detail-text mt-2">
                    <strong>Others:</strong> ZB716 (China startup, Phase 1, oral fulvestrant equivalent, VC-funded ~$50M, competitive on cost). CT.gov/NMPA entries show ~5 China-led trials, phases 1-2, designs single-arm with ORR focus; funding/licensing: SciClone sub-licensed elacestrant for China ($500M deal), signaling out-licensing to West.
                </p>

                <p class="detail-text mt-2">
                    Inflation high in China data (e.g., over-reported PROs), but confirmatory US/EU trials mitigate; ahead programs could undercut Vepdegestrant on price in Asia.
                </p>
            </div>

            <div class="reference-list">
                Sources: <a href="https://www.menarini.com/en-us/news/news-detail/menarini-group-and-sciclone-pharmaceuticals-announce-exclusive-sub-licensing-collaboration-to-develop-and-commercialize-orserdu174-elacestrant-in-china-to-address-advanced-or-metastatic-breast-cancer.html" target="_blank" class="link-btn">SciClone Licensing Deal</a> | 
                <a href="https://ascopubs.org/doi/10.1200/JCO.23.01500" target="_blank" class="link-btn">ASCO Competition Analysis</a>
            </div>
        </div>
    </div>

    <!-- 6. Geographic/Cultural Biases -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>6. Geographic & Cultural Biases in AE/PRO Reporting</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">Regional Reporting Variations</h4>
                <p class="detail-text">
                    Trials include sites in US/EU (majority), China/Japan/LatAm (~20-30%), raising biases: In China/Japan, cultural respect for physicians leads to under-reported AEs (e.g., zeros in PROs) and over-reported benefits, per surveys showing 20-30% lower AE rates vs US.
                </p>
            </div>

            <div class="metric-grid mt-4">
                <div class="metric-card">
                    <div class="metric-label">US/EU Sites</div>
                    <div class="metric-value">70%</div>
                    <div class="metric-detail">Majority enrollment</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Asia Sites</div>
                    <div class="metric-value">20-30%</div>
                    <div class="metric-detail">China/Japan/LatAm</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">AE Under-reporting</div>
                    <div class="metric-value">20-30%</div>
                    <div class="metric-detail">Lower in Asia vs US</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">PRO Non-response</div>
                    <div class="metric-value">10-15%</div>
                    <div class="metric-detail">Missingness in Asia</div>
                </div>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Mitigation Strategies Employed</h4>
                <p class="detail-text">
                    Missingness high in Asia (10-15% PRO non-response); LatAm similar due to access issues. Vepdegestrant's Phase 1b China study showed consistent safety (nausea/fatigue low-grade), but global AE rates (87% any-grade) may mask under-reporting.
                </p>

                <p class="detail-text mt-2">
                    <strong>Mitigation approaches:</strong> Investigator-reported AEs prioritized; PRO tools culturally adapted (e.g., EORTC QLQ-C30 validated in Mandarin); site training on reporting; US repeat dosing in bridging.
                </p>

                <p class="detail-text mt-2">
                    <strong>Flags:</strong> Inflated efficacy in China cohorts (CBR ~50% mutants) could mislead if not adjusted; regulators may require subgroup analyses.
                </p>
            </div>

            <div class="reference-list">
                Sources: <a href="https://www.researchgate.net/publication/289709341_Cross-cultural_surveys_on_patient_views_of_adverse_events_between_China_and_Japan" target="_blank" class="link-btn">Cross-Cultural AE Survey</a> | 
                <a href="https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0006" target="_blank" class="link-btn">Asia Medicine Analysis</a>
            </div>
        </div>
    </div>

    <!-- 7. Economic/Financing Thresholds -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>7. Economic & Financing Thresholds Analysis</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">Phase 3 Financial Requirements</h4>
                <p class="detail-text">
                    Phase 3 costs for Vepdegestrant estimated $500M-$1B total (VERITAC-2/3 ~$200-300M each, including global sites), shared 50/50 with Pfizer.
                </p>
            </div>

            <div class="metric-grid mt-4">
                <div class="metric-card">
                    <div class="metric-label">Total Phase 3 Cost</div>
                    <div class="metric-value">$500M-1B</div>
                    <div class="metric-detail">VERITAC-2/3 combined</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Arvinas Cash</div>
                    <div class="metric-value">$861M</div>
                    <div class="metric-detail">Q2 2025 position</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Cash Runway</div>
                    <div class="metric-value">H2 2028</div>
                    <div class="metric-detail">Post-restructuring</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Operations Spend</div>
                    <div class="metric-value">$177M</div>
                    <div class="metric-detail">Annual burn rate</div>
                </div>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Partnership Economics & Thresholds</h4>
                <p class="detail-text">
                    Arvinas' balance sheet: $861M cash as of Q2 2025, runway to H2 2028, post-$177M operations spend. Pfizer's $650M upfront + $350M equity (2021 deal) funds progression; thresholds appear high (proceeded despite non-significant overall PFS), with investor alignment via profit-sharing.
                </p>

                <p class="detail-text mt-2">
                    <strong>Red flags:</strong> Arvinas' 33% workforce cut (2025) to extend runway, but partnership mitigates financial risk.
                </p>
            </div>

            <div class="reference-list">
                Sources: <a href="https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-global-collaboration-develop" target="_blank" class="link-btn">Pfizer Partnership Deal</a> | 
                <a href="https://ir.arvinas.com/node/11636/pdf" target="_blank" class="link-btn">Arvinas SEC Filings</a>
            </div>
        </div>
    </div>

    <!-- 8. Operational Disclosure -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>8. Operational Disclosure & Documentation Consistency</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">ClinicalTrials.gov & Protocol Transparency</h4>
                <p class="detail-text">
                    CT.gov entries (e.g., NCT05654623) consistent: Protocol versions updated (e.g., Amendment for IB data), no gaps in prior work disclosure (Phase 1/2 linked).
                </p>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Documentation Review Findings</h4>
                <p class="detail-text">
                    IB content aligns (safety from Phase 1: no DLTs); mismatches minor (enrollment updates timely). Transparency high, with all cohorts reported; no red flags like hidden safety signals.
                </p>

                <p class="detail-text mt-2">
                    <strong>Key verifications:</strong>
                    <br>• NCT entries match protocol designs
                    <br>• Protocol versions show appropriate amendments
                    <br>• Investigator brochure content consistent with safety data
                    <br>• No gaps or mismatches across documents
                    <br>• All prior work appropriately disclosed
                </p>
            </div>

            <div class="reference-list">
                Sources: <a href="https://cdn.clinicaltrials.gov/large-docs/52/NCT05463952/Prot_000.pdf" target="_blank" class="link-btn">Protocol Documents</a> | 
                <a href="https://www.clinicaltrials.gov/study/NCT05654623" target="_blank" class="link-btn">VERITAC-2 Registry</a>
            </div>
        </div>
    </div>

    <!-- 9. Line of Therapy & Label Implications -->
    <div class="expandable-section">
        <div class="expandable-header" onclick="toggleSection(this)">
            <span>9. Line-of-Therapy Positioning & Label Trajectory</span>
            <span>▼</span>
        </div>
        <div class="expandable-content">
            <div class="highlight-box">
                <h4 class="font-semibold mb-2">Regulatory Positioning Strategy</h4>
                <p class="detail-text">
                    Intended 2L for ESR1-mut post-ET/CDK4/6, per VERITAC-2; FDA/EMA likely approve here (precedent: elacestrant 2L/3L).
                </p>
            </div>

            <div class="metric-grid mt-4">
                <div class="metric-card">
                    <div class="metric-label">Initial Position</div>
                    <div class="metric-value">2L ESR1-mut</div>
                    <div class="metric-detail">Post-CDK4/6i + ET</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Peak Sales (2L)</div>
                    <div class="metric-value">$500M</div>
                    <div class="metric-detail">Mutant-limited</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Expansion to 1L</div>
                    <div class="metric-value">$1-2B</div>
                    <div class="metric-detail">If VERITAC-3 positive</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Label Risk</div>
                    <div class="metric-value">3L</div>
                    <div class="metric-detail">If SoC unsettled</div>
                </div>
            </div>

            <div class="data-card mt-4">
                <h4 class="font-semibold mb-2">Commercial Trajectory Analysis</h4>
                <p class="detail-text">
                    If VERITAC-3 positive, expand to 1L combo; otherwise, combo-only or 3L risk if SoC unsettled (e.g., no clear 1L mutant data).
                </p>

                <p class="detail-text mt-2">
                    <strong>Commercial trajectory:</strong> Peak sales $1-2B if 1L/2L broad, but mutant-limited ~$500M. The label positioning will critically determine commercial success, with second-line ESR1-mutant approval as the base case, but potential for earlier-line expansion based on ongoing trials.
                </p>
            </div>

            <div class="reference-list">
                Sources: <a href="https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-submission-new-drug-application-us-fda" target="_blank" class="link-btn">NDA Submission Details</a> | 
                <a href="https://www.pfizeroncologydevelopment.com/clinical_trial/nct06206837" target="_blank" class="link-btn">Pfizer Oncology Pipeline</a>
            </div>
        </div>
    </div>

    <!-- Investment Summary -->
    <div class="data-card mt-6">
        <h3 class="text-xl font-bold mb-4">Comprehensive Analysis Conclusion</h3>
        <p class="detail-text">
            This comprehensive analysis draws on clinical trial data, regulatory filings, analyst insights, and competitive benchmarks to evaluate the program across critical dimensions, including regulatory shaping, standard of care context, success probabilities, competition (with emphasis on China-origin assets), reporting biases, financing, disclosures, and label prospects.
        </p>
        
        <p class="detail-text mt-2">
            The evaluation integrates global perspectives, acknowledging regional variations in care and data interpretation, while prioritizing primary sources like clinicaltrials.gov entries and company releases for accuracy. With an 80-90% PTRS for ESR1-mutant approval and strong partnership backing from Pfizer, vepdegestrant represents a compelling late-stage oncology investment opportunity despite competitive pressures and geographic reporting complexities.
        </p>
    </div>
</div>
            <!-- Clinical & Regulatory Tab -->
            <div id="clinical" class="tab-content ">
                <div class="section-title">1. Clinical & Regulatory Diligence</div>
                
                <!-- Trial Design & Endpoints -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.1 Trial Design & Endpoints</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">VERITAC-2 Phase 3 Design Overview</h4>
                            <p class="detail-text">
                                VERITAC-2 (NCT05654623) is a global randomized Phase 3 study enrolling 624 patients across 26 countries, comparing once-daily oral vepdegestrant (200mg) versus intramuscular fulvestrant (500mg) in ER+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor plus endocrine therapy.
                            </p>
                        </div>

                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">Co-Primary Endpoints</div>
                                <div class="metric-value">PFS</div>
                                <div class="metric-detail">ESR1-mutant & ITT populations</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Randomization</div>
                                <div class="metric-value">1:1</div>
                                <div class="metric-detail">Stratified by ESR1 mutation status</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Comparator</div>
                                <div class="metric-value">Fulvestrant</div>
                                <div class="metric-detail">Standard-of-care SERD</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Blinding</div>
                                <div class="metric-value">Open-label</div>
                                <div class="metric-detail">BICR for PFS assessment</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Secondary Endpoints:</strong> Overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR), duration of response (DoR), and patient-reported outcomes. The design reflects regulatory precedent from elacestrant (Orserdu), which targeted ESR1-mutant tumors for efficacy claims.
                        </p>

                        <p class="detail-text">
                            <strong>Geographic Distribution:</strong> Trial enrollment was well-balanced across North America, Europe, and Asia to support global regulatory filings. No major protocol amendments have been reported publicly, suggesting stable trial execution.
                        </p>

                        <div class="reference-list">
                            Sources: <a href="https://clinicaltrials.gov/ct2/show/NCT05654623" target="_blank" class="link-btn">ClinicalTrials.gov</a> | 
                            <a href="https://www.pfizer.com/news/press-release" target="_blank" class="link-btn">Pfizer Press Release</a>
                        </div>
                    </div>
                </div>

                <!-- Efficacy Results -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.2 Clinical Efficacy Results</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Primary Endpoint Achievement</h4>
                            <p class="detail-text">
                                In ESR1-mutant patients (43% of trial population), vepdegestrant achieved a statistically significant and clinically meaningful PFS improvement, reducing risk of progression by 43% versus fulvestrant.
                            </p>
                        </div>

                        <canvas id="pfsChart" class="chart-container"></canvas>

                        <div class="metric-grid mt-4">
                            <div class="metric-card">
                                <div class="metric-label">ESR1-mut Median PFS</div>
                                <div class="metric-value">5.0 mo</div>
                                <div class="metric-detail">vs 2.1 mo fulvestrant</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Hazard Ratio</div>
                                <div class="metric-value">0.57</div>
                                <div class="metric-detail">95% CI: 0.42-0.77, p<0.001</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">6-mo PFS Rate</div>
                                <div class="metric-value">45.2%</div>
                                <div class="metric-detail">vs 22.7% fulvestrant</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Clinical Benefit Rate</div>
                                <div class="metric-value">42.1%</div>
                                <div class="metric-detail">vs 20.2% (OR 2.88, p<0.001)</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>ITT Population Results:</strong> In the overall intent-to-treat population, vepdegestrant did not reach statistical significance - median PFS 3.7 vs 3.6 months (HR 0.83, 95% CI 0.68-1.02, p=0.07). This reflects that vepdegestrant's benefit is concentrated in tumors harboring ESR1 mutations, likely due to those mutations driving resistance to prior aromatase inhibitors.
                        </p>

                        <p class="detail-text">
                            <strong>Objective Response Rate:</strong> In ESR1-mutant patients, ORR was 18.6% with vepdegestrant versus 4.0% with fulvestrant (OR 5.45, p=0.001). Responses were durable with median duration not reached at data cutoff.
                        </p>

                        <p class="detail-text">
                            <strong>Overall Survival Data:</strong> OS data remain immature with less than 25% of events recorded. However, the observed efficacy on PFS and tumor response is compelling for this refractory population and parallels elacestrant's Phase 3 results (HR ~0.55, median PFS 3.8 vs 1.9 months in ESR1-mut patients).
                        </p>

                        <div class="reference-list">
                            Sources: NEJM Publication | ASCO 2025 Late-Breaker Abstract | Pfizer/Arvinas Joint Announcement
                        </div>
                    </div>
                </div>

                <!-- Phase 2 to Phase 3 Transition -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.3 Phase 2 Data & Transition to Phase 3</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <p class="detail-text">
                            The VERITAC Phase 2 expansion provided strong rationale for Phase 3 advancement. In heavily pretreated ER+ breast cancer patients (median 3-4 prior lines), vepdegestrant monotherapy achieved clinical benefit rate ~47% in ESR1-mutant tumors and median PFS ~5.5 months in that subgroup.
                        </p>

                        <p class="detail-text">
                            This signal is remarkably consistent with the Phase 3 ESR1-mutant PFS (5.0 months), indicating a reproducible effect size. Some patients in Phase 2 remained on drug ≥48 weeks. The Phase 2 also demonstrated substantial ER degradation and tumor marker reduction.
                        </p>

                        <p class="detail-text">
                            <strong>Interim Analyses:</strong> There was no early termination for futility or overwhelming efficacy. The readout was at the planned final PFS analysis (58% of PFS events in vepdegestrant arm), suggesting straightforward trial conduct. An earlier topline announcement in March 2025 noted the positive ESR1-mutant result, with data then presented at ASCO 2025 as a late-breaker and published in NEJM.
                        </p>
                    </div>
                </div>

                <!-- Safety Profile -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.4 Safety Profile Analysis</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Overall Safety Summary</h4>
                            <p class="detail-text">
                                Vepdegestrant was generally well-tolerated with a favorable safety profile relative to standard endocrine therapy. In VERITAC-2, 87% of patients on vepdegestrant experienced any treatment-emergent adverse event versus 81% on fulvestrant.
                            </p>
                        </div>

                        <table class="ae-table">
                            <thead>
                                <tr>
                                    <th>Adverse Event</th>
                                    <th>Vepdegestrant (%)</th>
                                    <th>Fulvestrant (%)</th>
                                    <th>Clinical Significance</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>Fatigue</td>
                                    <td>27%</td>
                                    <td>16%</td>
                                    <td>Mostly Grade 1-2</td>
                                </tr>
                                <tr>
                                    <td>ALT/AST elevation</td>
                                    <td>~14%</td>
                                    <td>10%</td>
                                    <td>Modest transaminase elevations</td>
                                </tr>
                                <tr>
                                    <td>Nausea</td>
                                    <td>13.5%</td>
                                    <td>9%</td>
                                    <td>Much lower than elacestrant (35%)</td>
                                </tr>
                                <tr>
                                    <td>Anemia</td>
                                    <td>12%</td>
                                    <td>8%</td>
                                    <td>Manageable</td>
                                </tr>
                                <tr>
                                    <td>Neutropenia</td>
                                    <td>12%</td>
                                    <td>5%</td>
                                    <td>Expected with mechanism</td>
                                </tr>
                                <tr>
                                    <td>Vomiting</td>
                                    <td>6.4%</td>
                                    <td>-</td>
                                    <td>Low incidence</td>
                                </tr>
                            </tbody>
                        </table>

                        <div class="metric-grid mt-4">
                            <div class="metric-card">
                                <div class="metric-label">Grade ≥3 TEAEs</div>
                                <div class="metric-value">23.4%</div>
                                <div class="metric-detail">vs 17.6% fulvestrant</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Serious AEs</div>
                                <div class="metric-value">10%</div>
                                <div class="metric-detail">vs 9% fulvestrant</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Discontinuation Rate</div>
                                <div class="metric-value">3%</div>
                                <div class="metric-detail">vs 1% fulvestrant</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Dose Reductions</div>
                                <div class="metric-value"><5%</div>
                                <div class="metric-detail">Excellent tolerability</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Key Safety Differentiator:</strong> The low GI toxicity (13.5% nausea) is a key differentiator versus elacestrant (35% nausea rate). This should improve patient quality of life and compliance. No treatment-related deaths occurred. Only ~8% had grade ≥3 treatment-related AEs on vepdegestrant.
                        </p>
                    </div>
                </div>

                <!-- Regulatory Status -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.5 Regulatory Status & Interactions</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="regulatory-flow">
                            <div class="flow-node completed">
                                <div class="flow-arrow">→</div>
                                <strong>Fast Track</strong>
                                <p class="text-sm mt-1">Granted Feb 2024</p>
                                <p class="text-xs text-gray-500">Monotherapy ER+/HER2-</p>
                            </div>
                            <div class="flow-node completed">
                                <div class="flow-arrow">→</div>
                                <strong>End of Phase 2</strong>
                                <p class="text-sm mt-1">FDA Meeting</p>
                                <p class="text-xs text-gray-500">2023</p>
                            </div>
                            <div class="flow-node completed">
                                <div class="flow-arrow">→</div>
                                <strong>Phase 3 Positive</strong>
                                <p class="text-sm mt-1">VERITAC-2 Met Primary</p>
                                <p class="text-xs text-gray-500">March 2025</p>
                            </div>
                            <div class="flow-node active">
                                <div class="flow-arrow">→</div>
                                <strong>NDA Accepted</strong>
                                <p class="text-sm mt-1">Priority Review</p>
                                <p class="text-xs text-gray-500">2H 2025</p>
                            </div>
                            <div class="flow-node">
                                <strong>PDUFA Date</strong>
                                <p class="text-sm mt-1">FDA Decision</p>
                                <p class="text-xs text-gray-500">Q1 2026 (Expected)</p>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            The FDA has accepted the New Drug Application for vepdegestrant for ER+/HER2− advanced breast cancer with ESR1 mutation after endocrine therapy. Fast Track designation was granted in February 2024. The NDA filing (submitted 2H 2025) was based on VERITAC-2 results, with PDUFA target action date expected in Q1 2026.
                        </p>

                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Regulatory Risk Considerations</h4>
                            <div class="risk-item">
                                <div class="risk-indicator risk-low"></div>
                                <div>
                                    <strong>Companion Diagnostic:</strong> ESR1 mutation testing required. FDA typically requires parallel approval or validated test. For elacestrant, Guardant360 CDx was approved for detecting ESR1 mutations.
                                </div>
                            </div>
                            <div class="risk-item">
                                <div class="risk-indicator risk-medium"></div>
                                <div>
                                    <strong>Label Scope:</strong> Likely restricted to ESR1-mutant patients who have progressed on AI+CDK4/6i. More restrictive labeling could narrow market.
                                </div>
                            </div>
                            <div class="risk-item">
                                <div class="risk-indicator risk-low"></div>
                                <div>
                                    <strong>Post-Marketing Requirements:</strong> Given immature OS data, FDA may require confirmatory survival data or real-world evidence follow-up.
                                </div>
                            </div>
                            <div class="risk-item">
                                <div class="risk-indicator risk-low"></div>
                                <div>
                                    <strong>Manufacturing (CMC):</strong> NDA acceptance indicates adequate CMC data. Vepdegestrant is a synthetic small molecule (PROTAC), larger than typical kinase inhibitors.
                                </div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>EMA & Other Agencies:</strong> The EMA's CHMP has historically required robust data in subsets. Given EMA recently recommended approval of elacestrant for ESR1-mut disease, it is likely to similarly accept vepdegestrant's data. Vepdegestrant's absolute PFS gain of ~3 months is larger than elacestrant's ~2 month gain, strengthening the case.
                        </p>

                        <div class="reference-list">
                            Sources: FDA Fast Track Announcement | Arvinas SEC Filings | Pfizer Regulatory Updates
                        </div>
                    </div>
                </div>
            </div>

            <!-- Scientific & IP Tab -->
            <div id="scientific" class="tab-content">
                <div class="section-title">2. Scientific & Intellectual Property Diligence</div>

                <!-- Mechanism of Action -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>2.1 Mechanism of Action & Scientific Rationale</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">PROTAC Technology Innovation</h4>
                            <p class="detail-text">
                                Vepdegestrant (ARV-471) is a first-in-class oral PROTAC (Proteolysis-Targeting Chimera) targeting the estrogen receptor. It consists of an ER-binding ligand linked to an E3 ubiquitin ligase recruiter. By binding both, it tags the ER for destruction via the proteasome.
                            </p>
                        </div>

                        <p class="detail-text">
                            This mechanism leads to near-complete ERα protein degradation in preclinical models. Vepdegestrant degrades both wild-type ER and mutant ER (including ESR1 ligand-binding domain mutations that confer resistance to aromatase inhibitors and fulvestrant).
                        </p>

                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">ER Degradation</div>
                                <div class="metric-value">>90%</div>
                                <div class="metric-detail">In tumor biopsies at 200mg</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Target</div>
                                <div class="metric-value">ERα/ESR1</div>
                                <div class="metric-detail">Including mutant forms</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">E3 Ligase</div>
                                <div class="metric-value">Cereblon</div>
                                <div class="metric-detail">Validated ligase target</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Molecular Weight</div>
                                <div class="metric-value">>800 Da</div>
                                <div class="metric-detail">Larger than typical SMIs</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Scientific Validation:</strong> ER is a well-known oncogenic driver in ~70% of breast cancers. Estrogen deprivation or receptor blockade improves survival in this disease. However, existing endocrine therapies have limitations - tumors acquire resistance often via ESR1 mutations that keep ER signaling active.
                        </p>

                        <p class="detail-text">
                            <strong>Advantages over Fulvestrant:</strong> Fulvestrant, a SERD, can degrade ER but has incomplete and variable degradation due to suboptimal PK and need for injections. Vepdegestrant's PROTAC approach achieves more potent and comprehensive ER knockdown inside tumor cells. Preclinical comparisons showed vepdegestrant causing greater tumor shrinkage than fulvestrant in ER-driven xenograft models, with additive efficacy when combined with CDK4/6 inhibitors.
                        </p>

                        <p class="detail-text">
                            <strong>Historic Achievement:</strong> Vepdegestrant is the first PROTAC ever to demonstrate improved outcomes in a Phase 3 trial, essentially validating targeted protein degradation in oncology. This novelty differentiates vepdegestrant from "me-too" SERDs.
                        </p>
                    </div>
                </div>

                <!-- Differentiation from Other SERDs -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>2.2 Differentiation from Competitive Therapies</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <table class="trial-table">
                            <thead>
                                <tr>
                                    <th>Drug</th>
                                    <th>Company</th>
                                    <th>Mechanism</th>
                                    <th>PFS Benefit (ESR1-mut)</th>
                                    <th>Key Differentiator</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td><strong>Vepdegestrant</strong></td>
                                    <td>Pfizer/Arvinas</td>
                                    <td>PROTAC</td>
                                    <td>5.0 vs 2.1 mo (2.9 mo gain)</td>
                                    <td>Superior ER degradation, low nausea</td>
                                </tr>
                                <tr>
                                    <td>Elacestrant</td>
                                    <td>Menarini</td>
                                    <td>Oral SERD</td>
                                    <td>3.8 vs 1.9 mo (1.9 mo gain)</td>
                                    <td>First approved, 35% nausea rate</td>
                                </tr>
                                <tr>
                                    <td>Camizestrant</td>
                                    <td>AstraZeneca</td>
                                    <td>Oral SERD</td>
                                    <td>~6.3 vs 2.2 mo (Ph2)</td>
                                    <td>Phase 3 ongoing, bradycardia risk</td>
                                </tr>
                                <tr>
                                    <td>Imlunestrant</td>
                                    <td>Eli Lilly</td>
                                    <td>Oral SERD</td>
                                    <td>Program discontinued</td>
                                    <td>Failed Phase 3</td>
                                </tr>
                                <tr>
                                    <td>Amcenestrant</td>
                                    <td>Sanofi</td>
                                    <td>Oral SERD</td>
                                    <td>Program terminated</td>
                                    <td>Failed AMEERA-5</td>
                                </tr>
                            </tbody>
                        </table>

                        <p class="detail-text mt-4">
                            <strong>Key Scientific Differentiators:</strong> Biochemically, PROTACs can achieve >90% degradation of target protein in cells, whereas traditional SERDs often plateau at lower levels. Clinically, vepdegestrant's 5.0-month median PFS in ESR1-mut patients versus 2.1 with fulvestrant was a 2.9-month benefit - modestly superior to elacestrant's 1.9-month benefit.
                        </p>

                        <p class="detail-text">
                            The success of vepdegestrant where others failed (Sanofi's amcenestrant, Lilly's imlunestrant both had Phase 3 failures) suggests achieving sufficient ER antagonism or degradation is challenging. Vepdegestrant's success implies a scientific edge through the PROTAC mechanism.
                        </p>
                    </div>
                </div>

                <!-- Combination Potential -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>2.3 Combination Biology & Future Development</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Combination Studies</h4>
                            
                            <p class="detail-text">
                                <strong>CDK4/6 Inhibitor Combination:</strong> Phase 1b combination with palbociclib showed good efficacy (median PFS 13.9 months, CBR ~63%) but revealed pharmacokinetic interaction requiring dose adjustment. Vepdegestrant increased palbociclib exposure, possibly via metabolic interaction (CYP3A4).
                            </p>

                            <p class="detail-text">
                                <strong>mTOR Inhibitor Combination:</strong> Phase 1b TACTIVE-E trial combining vepdegestrant with everolimus was initiated to overcome PI3K/AKT-mediated resistance. This could open use in ESR1-mutated, PI3K-activated tumors.
                            </p>

                            <p class="detail-text">
                                <strong>Neoadjuvant Setting:</strong> Vepdegestrant is being tested in early breast cancer to determine if profound ER degradation can shrink tumors pre-surgery. This could position it for adjuvant or earlier-line usage eventually.
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Drug-Drug Interactions</h4>
                            <p class="detail-text">
                                <strong>P-gp Substrate Interaction:</strong> Coadministration doubled dabigatran exposure and caused minor (~11%) rosuvastatin exposure increase in healthy volunteers. Vepdegestrant can clinically affect P-gp substrates, requiring label warnings and management strategies.
                            </p>
                        </div>
                    </div>
                </div>

                <!-- Intellectual Property -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>2.4 Intellectual Property Analysis</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Patent Portfolio Overview</h4>
                            <p class="detail-text">
                                Arvinas holds robust IP on vepdegestrant with issued composition-of-matter patents in the U.S. and key markets covering the molecule. Base patents (filed ~2018) will expire in 2033, not including potential extensions.
                            </p>
                        </div>

                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">Patent Expiry</div>
                                <div class="metric-value">2033</div>
                                <div class="metric-detail">Base patents</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">With Extension</div>
                                <div class="metric-value">~2038</div>
                                <div class="metric-detail">Up to 5 years PTE</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Market Exclusivity</div>
                                <div class="metric-value">10-13 years</div>
                                <div class="metric-detail">Post-launch protection</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Yale License</div>
                                <div class="metric-value">1-2%</div>
                                <div class="metric-detail">Expected royalty</div>
                            </div>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Trade Secret Litigation - Accutar Case</h4>
                            <p class="detail-text">
                                Arvinas is engaged in litigation with Accutar Biotechnology and former employee Dr. Qian over alleged trade secret theft related to ER degrader program. Arvinas claims the ex-employee took confidential information to Accutar in 2018. Discovery revealed hundreds of Arvinas' internal files on Accutar devices.
                            </p>
                            <p class="detail-text">
                                Arvinas expanded its list of misappropriated trade secrets from 126 to 853 items after discovery. This suggests extensive proprietary know-how in PROTAC design. Accutar is developing AC682, an "AI-designed" oral SERD, potentially creating future competition.
                            </p>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Freedom to Operate:</strong> Vepdegestrant is a novel chemical entity with no known blocking patents from competitors. Arvinas, as a PROTAC technology pioneer from Yale University research, has wide patent estate on the platform with defensive depth against rivals.
                        </p>
                    </div>
                </div>
            </div>

            <!-- Commercial & Market Tab -->
            <div id="commercial" class="tab-content">
                <div class="section-title">3. Commercial & Market Diligence</div>

                <!-- Market Opportunity -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>3.1 Target Population & Market Sizing</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Addressable Market Overview</h4>
                            <p class="detail-text">
                                Breast cancer represents ~2.3 million new cases annually globally, with ~320,000 new cases expected in the U.S. in 2025. Approximately 70% are ER+/HER2− (hormone receptor-positive), roughly 160-170k new ER+ cases per year in the U.S.
                            </p>
                        </div>

                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">Global BC Incidence</div>
                                <div class="metric-value">2.3M</div>
                                <div class="metric-detail">Annual new cases</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">ER+ Prevalence</div>
                                <div class="metric-value">70%</div>
                                <div class="metric-detail">Of all breast cancers</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">ESR1 Mutation Rate</div>
                                <div class="metric-value">40%</div>
                                <div class="metric-detail">Post-CDK4/6i progression</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">U.S. Target Population</div>
                                <div class="metric-value">~20k/year</div>
                                <div class="metric-detail">2L ESR1-mut patients</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Patient Flow Analysis:</strong> Nearly all ER+ metastatic patients receive first-line endocrine therapy (usually AI + CDK4/6i). On progression, ~30% of early-stage patients eventually develop metastatic disease. ESR1 mutations arise under AI therapy in ~40% of patients by second line, driving resistance.
                        </p>

                        <p class="detail-text">
                            <strong>Global Opportunity:</strong> If ~50-60k ER+ metastatic patients in the U.S. are on first-line therapy and ~40% progress with ESR1 mutations, that's ~20k patients per year eligible for vepdegestrant in second line. Globally, the annual treatable population could be ~50k+ patients worldwide initially.
                        </p>

                        <p class="detail-text">
                            <strong>Line Expansion Opportunities:</strong>
                            <br>• First-line metastatic: Replacing AI in combination with CDK4/6i (doubles target population)
                            <br>• Adjuvant setting: Hundreds of thousands globally per year (requires demonstrating relapse prevention)
                        </p>
                    </div>
                </div>

                <!-- Competitive Landscape -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>3.2 Competitive Landscape Analysis</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Direct Competitors - Current Market</h4>
                            
                            <p class="detail-text">
                                <strong>Fulvestrant (Faslodex):</strong> Long-time standard SERD, now generic (cheap) but low efficacy post-CDK setting (median PFS ~1.8-2.2 months). Requires monthly intramuscular injections (two large injections). Vepdegestrant beat fulvestrant on PFS (5.0 vs 2.1 mo), offering clear improvement.
                            </p>

                            <p class="detail-text">
                                <strong>Elacestrant (Orserdu):</strong> Menarini's oral SERD, FDA-approved January 2023 for ER+/HER2− metastatic breast cancer with ESR1 mutation after 1-2 prior endocrine therapies. Direct benchmark for vepdegestrant.
                                <br>• EMERALD trial: HR 0.55, median PFS 3.8 vs 1.9 months in ESR1-mut
                                <br>• Major issue: 35% nausea rate, 3.4% discontinuation due to AEs
                                <br>• Pricing: WAC $23,057/30×345mg; $7,686/30×86mg
                            </p>

                            <p class="detail-text">
                                <strong>Camizestrant (AstraZeneca):</strong> Potent oral SERD in Phase 3 (SERENA trials)
                                <br>• SERENA-2 Phase 2: HR 0.58, median PFS ~7.2 vs 3.7 mo at 75mg
                                <br>• ESR1-mutant subset: PFS ~6.3 vs 2.2 mo (HR 0.33)
                                <br>• Testing in first-line combo (SERENA-6) and second-line mono (SERENA-3)
                                <br>• Potential 2026-27 launch if successful
                                <br>• Safety concerns: bradycardia and ECG changes noted
                            </p>
                        </div>

                        <table class="trial-table mt-4">
                            <thead>
                                <tr>
                                    <th>Treatment Class</th>
                                    <th>Example</th>
                                    <th>Setting</th>
                                    <th>Competition Level</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>PI3K Inhibitors</td>
                                    <td>Alpelisib (Piqray)</td>
                                    <td>PIK3CA-mutant (~40%)</td>
                                    <td>Complementary</td>
                                </tr>
                                <tr>
                                    <td>AKT Inhibitors</td>
                                    <td>Capivasertib</td>
                                    <td>AKT-altered tumors</td>
                                    <td>Moderate</td>
                                </tr>
                                <tr>
                                    <td>mTOR Inhibitors</td>
                                    <td>Everolimus</td>
                                    <td>With endocrine therapy</td>
                                    <td>Low</td>
                                </tr>
                                <tr>
                                    <td>ADCs</td>
                                    <td>Sacituzumab govitecan</td>
                                    <td>Third-line, post-chemo</td>
                                    <td>Minimal</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                <!-- Pricing & Reimbursement -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>3.3 Pricing & Reimbursement Strategy</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">Expected U.S. Price</div>
                                <div class="metric-value">$10-15k</div>
                                <div class="metric-detail">Per month WAC</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Annual Cost</div>
                                <div class="metric-value">$120-180k</div>
                                <div class="metric-detail">Similar to CDK4/6i</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Gross-to-Net</div>
                                <div class="metric-value">35-45%</div>
                                <div class="metric-detail">Typical oncology discount</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Duration of Therapy</div>
                                <div class="metric-value">6-9 mo</div>
                                <div class="metric-detail">Average treatment</div>
                            </div>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Payer Strategy Considerations</h4>
                            
                            <p class="detail-text">
                                <strong>U.S. Payers:</strong> Will require confirmation of ESR1 mutation for reimbursement (automatic utilization management). May enforce step therapy requiring prior CDK4/6i + AI failure. Given significant PFS benefit, unlikely to require fulvestrant failure first for ESR1-mut patients.
                            </p>

                            <p class="detail-text">
                                <strong>Medicare/CMS:</strong> Most metastatic breast cancer patients are Medicare beneficiaries. Part D will cover on specialty tier. Protected from Medicare Price Negotiation for several years as new chemical entity.
                            </p>

                            <p class="detail-text">
                                <strong>Europe (NICE/G-BA):</strong> Will assess cost per QALY. Germany likely to see "added benefit for subgroup" allowing premium pricing. UK may require confidential discounts similar to elacestrant negotiations.
                            </p>

                            <p class="detail-text">
                                <strong>ICER Review Risk:</strong> Elacestrant showed ICER of $366,000 per QALY (not cost-effective at standard thresholds). Vepdegestrant may face similar scrutiny but better tolerability could improve value assessment.
                            </p>
                        </div>
                    </div>
                </div>

                <!-- Commercial Execution -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>3.4 Commercial Execution & Market Share</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Pfizer Commercial Advantages</h4>
                            <p class="detail-text">
                                Pfizer's co-commercialization provides ready sales force detailing to oncologists. Existing footprint in breast cancer (Ibrance/palbociclib) creates synergy - same oncologists prescribing Ibrance in first-line are targets for vepdegestrant in second-line.
                            </p>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Key Promotional Messages:</strong>
                            <br>• Nearly double 6-month PFS rate versus fulvestrant (45% vs 23%)
                            <br>• Proven in ESR1 mutations (precision oncology paradigm)
                            <br>• Better patient experience: oral (no injections), lower nausea than competitors
                            <br>• First successful PROTAC (innovation story)
                        </p>

                        <p class="detail-text">
                            <strong>Guideline Inclusion:</strong> Anticipate rapid inclusion in NCCN Guidelines as Category 1 recommendation for ESR1-mutant ER+ disease. ESMO and national guidelines will likewise include given NEJM publication.
                        </p>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Market Share Projections</h4>
                            <p class="detail-text">
                                <strong>Base Case:</strong> Peak sales ~$1-1.1B (Jefferies projection) assuming second-line use in major markets
                                <br><strong>Bull Case:</strong> Up to $2B if first-line usage realized
                                <br><strong>Conservative:</strong> $500M if limited to narrow ESR1-mut subset
                            </p>
                            
                            <p class="detail-text mt-2">
                                If approved late 2025/2026, vepdegestrant could capture significant share of ESR1-mutant patients. Despite elacestrant's 2-year head start, Pfizer's marketing muscle could overtake within 1-2 years. Peak year estimated around 2030.
                            </p>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Financial & Strategic Tab -->
            <div id="financial" class="tab-content">
                <div class="section-title">4. Financial & Strategic Diligence</div>

                <!-- Arvinas Financials -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>4.1 Arvinas Company Financials</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="metric-grid">
                            <div class="metric-card">
                                <div class="metric-label">Cash Position (Q2 2025)</div>
                                <div class="metric-value">$861.2M</div>
                                <div class="metric-detail">Cash & marketable securities</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Quarterly Burn</div>
                                <div class="metric-value">$93.9M</div>
                                <div class="metric-detail">R&D: $68.6M, G&A: $25.3M</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Cash Runway</div>
                                <div class="metric-value">2H 2028</div>
                                <div class="metric-detail">Post-restructuring</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Market Cap</div>
                                <div class="metric-value">~$570M</div>
                                <div class="metric-detail">Below cash value</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Recent Restructuring:</strong> May 1, 2025 - Arvinas announced pipeline reprioritization and 33% workforce reduction. Canceled two planned Phase 3 trials (first-line combo and second-line combo) to conserve cash and focus on core program. This significantly reduced burn rate and extended runway.
                        </p>

                        <p class="detail-text">
                            <strong>Market Valuation Disconnect:</strong> Stock price plunged 25% to ~$7.23/share after trial cancellations, giving market cap around $500-550M (below cash on hand). Enterprise value effectively negative, implying market skepticism despite positive Phase 3 data.
                        </p>
                    </div>
                </div>

                <!-- Partnership Economics -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>4.2 Pfizer Partnership Economics</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">July 2021 Collaboration Terms</h4>
                            <p class="detail-text">
                                Arvinas received $650 million upfront plus $350 million Pfizer equity investment at ~30% premium. Deal includes $400 million in regulatory milestones and $1.0 billion in commercial milestones.
                            </p>
                        </div>

                        <div class="metric-grid mt-4">
                            <div class="metric-card">
                                <div class="metric-label">Profit Share</div>
                                <div class="metric-value">50/50</div>
                                <div class="metric-detail">Global cost & profit split</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Upfront Payment</div>
                                <div class="metric-value">$650M</div>
                                <div class="metric-detail">Received 2021</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Equity Investment</div>
                                <div class="metric-value">$350M</div>
                                <div class="metric-detail">At premium valuation</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Total Milestones</div>
                                <div class="metric-value">$1.4B</div>
                                <div class="metric-detail">Regulatory + commercial</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>2025 Update:</strong> Both parties publicly indicated they may rework the 50/50 structure post-VERITAC-2 due to smaller initial market versus early expectations. This represents a material valuation swing factor to monitor.
                        </p>

                        <p class="detail-text">
                            <strong>Revenue Recognition:</strong> Arvinas recognizes collaboration revenue equal to 50% of net profits. In Q4 2024, revenue jumped by $102M mainly from Pfizer ARV-471 collaboration accounting. Upon approval, Arvinas could receive $100-200M milestone payment (part of $400M regulatory pot).
                        </p>
                    </div>
                </div>

                <!-- Valuation Scenarios -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>4.3 Valuation & Return Scenarios</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Risk-Adjusted NPV Analysis</h4>
                            
                            <p class="detail-text">
                                <strong>Mid-Case Scenario:</strong>
                                <br>• Peak global sales: $1.5B (~2030)
                                <br>• Arvinas share: 50% of profits
                                <br>• EBIT margin: 70% (conservative for small molecule)
                                <br>• Annual profit to Arvinas at peak: ~$525M
                                <br>• Patent protection to 2033-2038
                                <br>• NPV (10% discount): $2-4 billion
                                <br>• Risk-adjusted (90% PoS): $2-3 billion
                            </p>

                            <p class="detail-text mt-2">
                                <strong>Conservative Scenario:</strong>
                                <br>• Peak sales: $1B
                                <br>• Arvinas profit share: ~$350M/year
                                <br>• NPV: $1.5-2B
                            </p>

                            <p class="detail-text mt-2">
                                <strong>Bull Scenario:</strong>
                                <br>• Peak sales: $2B+ (with first-line expansion)
                                <br>• Arvinas profit share: ~$700M/year
                                <br>• NPV: $4-5B
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Investment Return Analysis</h4>
                            
                            <p class="detail-text">
                                <strong>Current Opportunity:</strong> With Arvinas trading at ~$7/share ($500M valuation) and negative enterprise value, potential 4x return if drug captures $1B sales by 2030. Corresponds to IRR of ~25-30% over 5 years.
                            </p>

                            <p class="detail-text">
                                <strong>Analyst Perspective:</strong> Trial cancellations represented ~40% of asset value per analysts, implying remaining program worth 60% of prior value. If Arvinas was $20/share before, 60% would be $12, yet stock fell to ~$7 (overshooting pessimism).
                            </p>
                        </div>
                    </div>
                </div>

                <!-- Exit Strategies -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>4.4 Exit Strategies & Strategic Options</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Acquisition by Pfizer</h4>
                            <p class="detail-text">
                                Pfizer might acquire Arvinas to secure full ownership of vepdegestrant profits. Currently gets 50% of profits while doing 50% of work. Acquisition of $1-2B (premium to current $500M market cap) logical if drug succeeds. Likely timing: post-approval once sales ramp (1-3 years).
                            </p>
                        </div>

                        <div class="data-card mt-2">
                            <h4 class="font-semibold mb-2">Royalty Monetization</h4>
                            <p class="detail-text">
                                Blackstone could structure royalty deal: pay ~$300M upfront for 5-10% of net sales from Arvinas' share. If sales hit $1B, yields $50M/year with decent IRR. Arvinas might consider to avoid equity dilution. Similar to Blackstone's Alnylam transaction.
                            </p>
                        </div>

                        <div class="data-card mt-2">
                            <h4 class="font-semibold mb-2">Public Market Exit</h4>
                            <p class="detail-text">
                                If not acquired, Arvinas transforms into commercial-stage company, potentially profitable by late decade on vepdegestrant revenues. Stock could re-rate on sales numbers with exit via public market if price appreciates.
                            </p>
                        </div>

                        <div class="data-card mt-2">
                            <h4 class="font-semibold mb-2">Structured Investment Options</h4>
                            <p class="detail-text">
                                • Tranched investment: Initial tranche now, second upon FDA approval
                                <br>• Convertible debt: Downside protection with upside via conversion
                                <br>• Arvinas has no significant debt (near zero), allowing secured position
                            </p>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Operational & Legal Tab -->
            <div id="operational" class="tab-content">
                <div class="section-title">5. Operational & Legal Diligence</div>

                <!-- Manufacturing -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>5.1 Manufacturing & CMC</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Manufacturing Overview</h4>
                            <p class="detail-text">
                                Vepdegestrant is a small molecule PROTAC (MW >800 Da) manufactured via chemical synthesis. NDA acceptance indicates FDA satisfaction with CMC modules. No manufacturing issues reported publicly.
                            </p>
                        </div>

                        <div class="metric-grid mt-4">
                            <div class="metric-card">
                                <div class="metric-label">Molecule Type</div>
                                <div class="metric-value">PROTAC</div>
                                <div class="metric-detail">Bifunctional small molecule</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Manufacturing</div>
                                <div class="metric-value">CMO-based</div>
                                <div class="metric-detail">Contract manufacturers</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Formulation</div>
                                <div class="metric-value">Oral tablet</div>
                                <div class="metric-detail">200mg daily dose</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Shelf Life</div>
                                <div class="metric-value">≥24 months</div>
                                <div class="metric-detail">Expected at room temp</div>
                            </div>
                        </div>

                        <p class="detail-text mt-4">
                            <strong>Supply Chain Components:</strong>
                            <br>• ER-ligand warhead synthesis
                            <br>• Linker production
                            <br>• E3 ligase binder (likely cereblon-targeting, thalidomide derivative)
                            <br>• Coupling and final drug substance
                        </p>

                        <p class="detail-text">
                            <strong>Scale-up Status:</strong> Phase 3 had 600+ patients, indicating multi-kilo batches produced reliably. Production for commercial demand (tens of kilograms API annually) within normal range for small molecules. Pfizer's involvement de-risks supply chain management.
                        </p>

                        <p class="detail-text">
                            <strong>COGS Analysis:</strong> Likely COGS per patient per year is few thousand dollars. At >$100k price point, gross margin ~90%+. No evidence of high manufacturing costs despite PROTAC complexity.
                        </p>
                    </div>
                </div>

                <!-- Legal Issues -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>5.2 Legal Issues & Liabilities</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Accutar Trade Secret Litigation</h4>
                            <p class="detail-text">
                                <strong>Case Details:</strong> Arvinas v. Accutar Biotechnology and Dr. Qian (former employee)
                                <br><strong>Filed:</strong> May 2022 in D. Del.
                                <br><strong>Allegations:</strong> Ex-employee took confidential ER/AR degrader information to Accutar in 2018
                                <br><strong>Discovery:</strong> Hundreds of Arvinas files found on Accutar devices
                                <br><strong>Trade Secrets:</strong> Expanded from 126 to 853 items after discovery
                                <br><strong>Impact:</strong> Accutar developing AC682 "AI-designed" oral SERD (potential future competition)
                                <br><strong>Status:</strong> Ongoing, possible trial 2025 or settlement
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Shareholder Lawsuits</h4>
                            <p class="detail-text">
                                After May 2025 stock drop (trial cancellations), two law firms announced investigations:
                                <br>• Pomerantz LLP: Investigating whether Arvinas misled investors
                                <br>• Kirby McInerney: Similar investigation
                                <br>• Focus: Whether risks were properly disclosed before trial cancellation
                                <br>• Expected outcome: Likely settlement (insured), few million dollars
                                <br>• Impact: Minimal operational/financial impact but highlights disclosure practices
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Contractual Obligations</h4>
                            <p class="detail-text">
                                <strong>Yale University License:</strong>
                                <br>• Arvinas founded on Yale PROTAC patents
                                <br>• Expected low single-digit royalties (1-2%) to Yale
                                <br>• Some patents co-owned with Yale
                                <br>• Milestone payments likely included
                            </p>

                            <p class="detail-text mt-2">
                                <strong>Pfizer Partnership Terms:</strong>
                                <br>• 50/50 global profit share (not royalty)
                                <br>• Change-of-control provisions likely included
                                <br>• Approval milestone expected ($100-200M from $400M regulatory pot)
                            </p>
                        </div>
                    </div>
                </div>

                <!-- Regulatory Compliance -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>5.3 Quality & Regulatory Compliance</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <p class="detail-text">
                            <strong>Quality Systems:</strong> Arvinas has Quality System for clinical manufacturing and pharmacovigilance. No known compliance issues or FDA 483 observations. Pfizer's quality infrastructure will govern commercial operations.
                        </p>

                        <p class="detail-text">
                            <strong>Regulatory Compliance Requirements:</strong>
                            <br>• Pharmacovigilance and adverse event monitoring (Pfizer-led globally)
                            <br>• Sunshine Act reporting (physician payments)
                            <br>• Promotional practices compliance
                            <br>• Medical affairs infrastructure
                        </p>

                        <p class="detail-text">
                            <strong>Environmental/Safety Considerations:</strong>
                            <br>• PROTAC synthesis involves potent thalidomide analogs (teratogenic)
                            <br>• Manufacturing must handle safely with appropriate containment
                            <br>• Pfizer has extensive experience with high-potency compounds
                        </p>

                        <p class="detail-text">
                            <strong>No Red Flags:</strong>
                            <br>• No FDA warning letters
                            <br>• No trial site 483s reported
                            <br>• No data integrity issues
                            <br>• No ethics violations
                        </p>
                    </div>
                </div>
            </div>

            <!-- Management & Team Tab -->
            <div id="management" class="tab-content">
                <div class="section-title">6. Management & Team Execution</div>

                <!-- Leadership -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>6.1 Leadership Experience</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="data-card">
                            <h4 class="font-semibold mb-2">CEO - John G. Houston, Ph.D.</h4>
                            <p class="detail-text">
                                • 30+ years pharma R&D experience
                                <br>• 18 years at Bristol-Myers Squibb leading discovery teams
                                <br>• Joined Arvinas 2017, became CEO
                                <br>• Advanced multiple PROTACs to clinic
                                <br>• Struck major partnerships (Pfizer, Genentech, Bayer)
                                <br>• Named among top biotech CEOs in 2021
                                <br>• Big pharma background provides network for deals
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Board & Scientific Advisors</h4>
                            <p class="detail-text">
                                • Board includes biotech investors and industry veterans
                                <br>• Scientific Advisory Board includes Craig Crews (Yale, PROTAC inventor)
                                <br>• Joint steering committees with Pfizer govern collaboration
                                <br>• Decision to halt trials was joint Arvinas-Pfizer strategic pivot
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Pfizer Partnership Team</h4>
                            <p class="detail-text">
                                • Dr. Chris Boshoff (CMO of Pfizer Oncology) publicly lauded results
                                <br>• Pfizer oncology has multiple approved drugs in breast cancer
                                <br>• Experienced regulatory team with track record (palbociclib, etc.)
                                <br>• Global commercial infrastructure in place
                            </p>
                        </div>
                    </div>
                </div>

                <!-- Execution Track Record -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>6.2 Team Execution Strengths & Risks</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Execution Achievements</h4>
                            <p class="detail-text">
                                • Successfully completed 600-patient global Phase 3 trial in ~2 years
                                <br>• Data quality high enough for NEJM publication
                                <br>• Timely topline (March 2025) and full data (ASCO May 2025)
                                <br>• Prompt NDA preparation and submission by mid-2025
                                <br>• Pfizer partnership instilled discipline and regulatory muscle
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Organizational Changes</h4>
                            <p class="detail-text">
                                <strong>May 2025 Restructuring:</strong>
                                <br>• 33% workforce reduction (~1/3 of staff)
                                <br>• R&D reprioritization to focus on vepdegestrant
                                <br>• Canceled two Phase 3 expansion trials
                                <br>• Impact: Hurt morale but necessary for capital preservation
                                <br>• Risk: Must retain key talent for regulatory/launch execution
                                <br>• Mitigation: Pfizer can fill gaps if needed
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Commercial Readiness</h4>
                            <p class="detail-text">
                                <strong>Arvinas Limitations:</strong>
                                <br>• No prior commercial drug launch experience
                                <br>• Would need to build commercial infrastructure
                                
                                <br><br><strong>Pfizer Mitigation:</strong>
                                <br>• Pfizer leads sales in most markets
                                <br>• Arvinas may co-promote in U.S. (small specialty team)
                                <br>• Arvinas focuses on medical affairs and KOL education
                                <br>• Commercial risk effectively eliminated by partnership
                            </p>
                        </div>

                        <div class="risk-item">
                            <div class="risk-indicator risk-medium"></div>
                            <div>
                                <strong>Investor Relations:</strong> Pomerantz investigation suggests investors felt blindsided by trial cancellations. Communication could have been better. Blackstone would likely require board observer rights for early insight.
                            </div>
                        </div>

                        <div class="risk-item mt-3">
                            <div class="risk-indicator risk-low"></div>
                            <div>
                                <strong>Pipeline Focus:</strong> Other programs (AR degraders for prostate, neuro programs) explicitly deprioritized to favor vepdegestrant. Shows disciplined capital allocation.
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Safety & Toxicology Tab -->
            <div id="safety" class="tab-content">
                <div class="section-title">7. Comprehensive Safety & Toxicology Profile</div>

                <!-- Phase 1 Safety -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>7.1 Phase 1/2 Safety Data (ARV-471-mBC-101)</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Dose Escalation Results</h4>
                            <p class="detail-text">
                                No dose-limiting toxicities observed up to 700mg daily (highest dose tested). Maximum tolerated dose not reached. Recommended Phase 2/3 dose: 200mg QD based on optimal ER degradation (89%) and tolerability.
                            </p>
                        </div>

                        <table class="ae-table">
                            <thead>
                                <tr>
                                    <th>Adverse Event</th>
                                    <th>All Grades (%)</th>
                                    <th>Grade 3 (%)</th>
                                    <th>Grade 4 (%)</th>
                                    <th>Led to Discontinuation</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>Nausea</td>
                                    <td>29%</td>
                                    <td>One patient</td>
                                    <td>0</td>
                                    <td>No (dose reduction in 1)</td>
                                </tr>
                                <tr>
                                    <td>Fatigue</td>
                                    <td>20%</td>
                                    <td>Rare</td>
                                    <td>0</td>
                                    <td>No</td>
                                </tr>
                                <tr>
                                    <td>Vomiting</td>
                                    <td>10%</td>
                                    <td>0</td>
                                    <td>0</td>
                                    <td>No</td>
                                </tr>
                                <tr>
                                    <td>Amylase/Lipase ↑</td>
                                    <td>Few</td>
                                    <td>Asymptomatic</td>
                                    <td>0</td>
                                    <td>No</td>
                                </tr>
                                <tr>
                                    <td>QTc prolongation</td>
                                    <td>Single patient</td>
                                    <td>Transient</td>
                                    <td>0</td>
                                    <td>No</td>
                                </tr>
                                <tr>
                                    <td>Venous embolism</td>
                                    <td>1 patient</td>
                                    <td>Post-biopsy</td>
                                    <td>0</td>
                                    <td>Yes (1 patient, <2%)</td>
                                </tr>
                            </tbody>
                        </table>

                        <p class="detail-text mt-4">
                            <strong>Key Safety Findings:</strong>
                            <br>• Only 1 patient (<2%) discontinued due to TRAE
                            <br>• Only 1 patient required dose reduction (Grade 3 nausea)
                            <br>• No Grade 4 treatment-related AEs
                            <br>• No liver function abnormalities or bradycardia (issues with other oral SERDs)
                        </p>
                    </div>
                </div>

                <!-- Phase 3 Safety -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>7.2 Phase 3 VERITAC-2 Comprehensive Safety Analysis</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <canvas id="safetyComparisonChart" class="chart-container"></canvas>

                        <div class="metric-grid mt-4">
                            <div class="metric-card">
                                <div class="metric-label">Any TEAE</div>
                                <div class="metric-value">87%</div>
                                <div class="metric-detail">vs 81% fulvestrant</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Grade ≥3 TEAE</div>
                                <div class="metric-value">23.4%</div>
                                <div class="metric-detail">vs 17.6% fulvestrant</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Serious AEs</div>
                                <div class="metric-value">10%</div>
                                <div class="metric-detail">vs 9% fulvestrant</div>
                            </div>
                            <div class="metric-card">
                                <div class="metric-label">Treatment Deaths</div>
                                <div class="metric-value">0</div>
                                <div class="metric-detail">No treatment-related deaths</div>
                            </div>
                        </div>

                        <table class="ae-table mt-4">
                            <thead>
                                <tr>
                                    <th>Most Common TEAEs</th>
                                    <th>Vepdegestrant</th>
                                    <th>Fulvestrant</th>
                                    <th>Difference</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>Fatigue</td>
                                    <td>27%</td>
                                    <td>16%</td>
                                    <td>+11%</td>
                                </tr>
                                <tr>
                                    <td>ALT elevation</td>
                                    <td>14%</td>
                                    <td>10%</td>
                                    <td>+4%</td>
                                </tr>
                                <tr>
                                    <td>AST elevation</td>
                                    <td>14%</td>
                                    <td>10%</td>
                                    <td>+4%</td>
                                </tr>
                                <tr>
                                    <td>Nausea</td>
                                    <td>13.5%</td>
                                    <td>9%</td>
                                    <td>+4.5%</td>
                                </tr>
                                <tr>
                                    <td>Anemia</td>
                                    <td>12%</td>
                                    <td>8%</td>
                                    <td>+4%</td>
                                </tr>
                                <tr>
                                    <td>Neutropenia</td>
                                    <td>12%</td>
                                    <td>5%</td>
                                    <td>+7%</td>
                                </tr>
                                <tr>
                                    <td>Arthralgia</td>
                                    <td>11%</td>
                                    <td>8%</td>
                                    <td>+3%</td>
                                </tr>
                                <tr>
                                    <td>Vomiting</td>
                                    <td>6.4%</td>
                                    <td>-</td>
                                    <td>-</td>
                                </tr>
                            </tbody>
                        </table>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Management of Adverse Events</h4>
                            <p class="detail-text">
                                • Discontinuation due to AEs: 3% vepdegestrant vs 1% fulvestrant
                                <br>• Dose reductions required: <5% of patients
                                <br>• Grade ≥3 treatment-related AEs: ~8%
                                <br>• Most AEs were Grade 1-2 and manageable with supportive care
                            </p>
                        </div>
                    </div>
                </div>

                <!-- Comparative Safety -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>7.3 Comparative Safety vs Other Oral SERDs</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="highlight-box">
                            <h4 class="font-semibold mb-2">Key Safety Advantages</h4>
                            <p class="detail-text">
                                Vepdegestrant's 13.5% nausea rate is dramatically lower than elacestrant's 35% rate - a major differentiator for patient quality of life and compliance.
                            </p>
                        </div>

                        <table class="trial-table">
                            <thead>
                                <tr>
                                    <th>Safety Parameter</th>
                                    <th>Vepdegestrant</th>
                                    <th>Elacestrant (Orserdu)</th>
                                    <th>Clinical Significance</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>Nausea (any grade)</td>
                                    <td>13.5%</td>
                                    <td>35%</td>
                                    <td>Major QoL advantage</td>
                                </tr>
                                <tr>
                                    <td>Discontinuation for AEs</td>
                                    <td>3%</td>
                                    <td>3.4%</td>
                                    <td>Comparable</td>
                                </tr>
                                <tr>
                                    <td>Bradycardia</td>
                                    <td>Not observed</td>
                                    <td>Small risk, monitoring required</td>
                                    <td>Safety advantage</td>
                                </tr>
                                <tr>
                                    <td>Liver toxicity</td>
                                    <td>Modest AST/ALT ↑</td>
                                    <td>Similar</td>
                                    <td>No significant issue</td>
                                </tr>
                                <tr>
                                    <td>Food requirement</td>
                                    <td>No</td>
                                    <td>Must take with food</td>
                                    <td>Convenience advantage</td>
                                </tr>
                                <tr>
                                    <td>Cholesterol monitoring</td>
                                    <td>Not required</td>
                                    <td>Required per label</td>
                                    <td>Less monitoring burden</td>
                                </tr>
                            </tbody>
                        </table>

                        <p class="detail-text mt-4">
                            <strong>Advantages over Fulvestrant:</strong>
                            <br>• Oral administration (no painful IM injections)
                            <br>• No injection site reactions
                            <br>• More convenient dosing schedule
                            <br>• Better efficacy with manageable safety
                        </p>
                    </div>
                </div>

                <!-- Special Populations -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>7.4 Special Populations & Drug Interactions</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-card">
                            <h4 class="font-semibold mb-2">Drug-Drug Interactions</h4>
                            <p class="detail-text">
                                <strong>P-glycoprotein Interactions:</strong>
                                <br>• Doubled dabigatran exposure (anticoagulant)
                                <br>• Minor increase (~11%) in rosuvastatin exposure
                                <br>• Clinical implication: Careful monitoring with P-gp substrates
                                <br>• Label will include interaction warnings
                            </p>

                            <p class="detail-text mt-2">
                                <strong>CYP3A4 Interactions:</strong>
                                <br>• Increased palbociclib exposure when combined
                                <br>• Required dose adjustment in combination trials
                                <br>• May affect other CYP3A4 substrates
                            </p>
                        </div>

                        <div class="data-card mt-4">
                            <h4 class="font-semibold mb-2">Regional Safety Data</h4>
                            <p class="detail-text">
                                <strong>China Bridging Study (n=9):</strong>
                                <br>• No new safety signals in Chinese patients
                                <br>• Comparable drug levels and tolerability
                                <br>• Supports global safety profile
                            </p>

                            <p class="detail-text mt-2">
                                <strong>Japan PK Study:</strong>
                                <br>• Similar findings to China study
                                <br>• No ethnic differences in safety
                            </p>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Complete Trial Analysis Tab -->
            <div id="oldtrials" class="tab-content">
                <div class="section-title">8. Complete Trial Portfolio Analysis</div>

                <!-- Trial Timeline -->
                <div class="timeline-container">
                    <div class="timeline-line"></div>
                    
                    <!-- Phase 1 First-in-Human -->
                    <div class="timeline-item">
                        <div class="timeline-dot"></div>
                        <div class="timeline-date">2019-2021</div>
                        <div class="timeline-content">
                            <h4 class="font-semibold">Phase 1 First-in-Human (ARV-471-mBC-101)</h4>
                            <p class="detail-text">
                                <strong>Design:</strong> Single-arm dose escalation, 30-700mg QD
                                <br><strong>Population:</strong> Heavily pretreated ER+/HER2- MBC (median 4 prior lines, all had CDK4/6i)
                                <br><strong>n=60:</strong> 47 evaluable for efficacy
                                <br><strong>Primary Endpoints:</strong> MTD, safety, preliminary efficacy
                            </p>
                            <p class="detail-text mt-2">
                                <strong>Key Results:</strong>
                                <br>• No DLTs up to 700mg (MTD not reached)
                                <br>• CBR: 40% (19/47 patients)
                                <br>• ORR: 3 PRs in 38 patients with measurable disease
                                <br>• 2 patients remained on treatment >18 months
                                <br>• Common TRAEs: nausea (29%), fatigue (20%), vomiting (10%)
                                <br>• RP2D selected: 200mg QD (89% ER degradation)
                            </p>
                            <div class="reference-list">
                                Source: <a href="https://www.pfizer.com/news/press-release" target="_blank" class="link-btn">Pfizer/Arvinas Press Release</a>
                            </div>
                        </div>
                    </div>

                    <!-- Phase 2 VERITAC -->
                    <div class="timeline-item">
                        <div class="timeline-dot"></div>
                        <div class="timeline-date">2021-2023</div>
                        <div class="timeline-content">
                            <h4 class="font-semibold">Phase 2 VERITAC Expansion</h4>
                            <p class="detail-text">
                                <strong>Design:</strong> Single-arm expansion at 200mg QD
                                <br><strong>Population:</strong> ER+/HER2- MBC after CDK4/6i (including ESR1-mut and WT)
                                <br><strong>n=~100:</strong> Enriched for ESR1 mutations
                                <br><strong>Primary Endpoints:</strong> ORR, CBR, safety
                            </p>
                            <p class="detail-text mt-2">
                                <strong>Key Results:</strong>
                                <br>• CBR: ~38% overall, ~50% in ESR1-mutant subset
                                <br>• Median PFS: ~5.5 months in ESR1-mutant
                                <br>• ORR: ~6% overall (heavily pretreated population)
                                <br>• Some patients ≥48 weeks on treatment
                                <br>• Confirmed activity enriched in ESR1-mutant tumors
                                <br>• Favorable tolerability maintained
                            </p>
                        </div>
                    </div>

                    <!-- Phase 1b Combination -->
                    <div class="timeline-item">
                        <div class="timeline-dot"></div>
                        <div class="timeline-date">2022-2024</div>
                        <div class="timeline-content">
                            <h4 class="font-semibold">Phase 1b Palbociclib Combination</h4>
                            <p class="detail-text">
                                <strong>Design:</strong> Vepdegestrant 200mg + Palbociclib 125mg
                                <br><strong>Population:</strong> CDK4/6i-naïve and pretreated cohorts
                                <br><strong>Primary:</strong> Safety, PK interaction, preliminary efficacy
                            </p>
                            <p class="detail-text mt-2">
                                <strong>Key Results:</strong>
                                <br>• Median PFS: 13.9 months (95% CI: 8.1-NR)
                                <br>• CBR: ~63% in earlier updates
                                <br>• ORR: ~59% in CDK4/6i-naïve patients
                                <br>• PK interaction: Vepdegestrant increased palbociclib exposure
                                <br>• Required dose adjustment strategy for future trials
                                <br>• Combination deemed viable with dose optimization
                            </p>
                            <div class="reference-list">
                                Note: First-line combination trial (VERITAC-3 precursor) was later canceled in May 2025 restructuring
                            </div>
                        </div>
                    </div>

                    <!-- Regional Bridging Studies -->
                    <div class="timeline-item">
                        <div class="timeline-dot"></div>
                        <div class="timeline-date">2023-2024</div>
                        <div class="timeline-content">
                            <h4 class="font-semibold">Regional PK/Safety Bridging Studies</h4>
                            
                            <div class="data-card mt-2">
                                <strong>China Bridging (NCT05732428):</strong>
                                <br>• n=9 Chinese patients with ER+/HER2- MBC
                                <br>• Single-arm, 200mg QD
                                <br>• Confirmed similar PK exposure and ER degradation
                                <br>• No new safety signals vs global population
                                <br>• Supports China inclusion in global trials
                                <br><a href="https://clinicaltrials.gov/ct2/show/NCT05732428" target="_blank" class="link-btn">View on ClinicalTrials.gov →</a>
                            </div>
                            
                            <div class="data-card mt-2">
                                <strong>Japan PK Study (NCT05463952):</strong>
                                <br>• Small cohort for Japanese regulatory requirements
                                <br>• Similar design to China study
                                <br>• Completed with no new signals
                                <br><a href="https://clinicaltrials.gov/ct2/show/NCT05463952" target="_blank" class="link-btn">View on ClinicalTrials.gov →</a>
                            </div>
                        </div>
                    </div>

                    <!-- Phase 3 VERITAC-2 -->
                    <div class="timeline-item">
                        <div class="timeline-dot" style="background: #ffc107;"></div>
                        <div class="timeline-date">2023-2025</div>
                        <div class="timeline-content">
                            <h4 class="font-semibold">🏆 Phase 3 VERITAC-2 (NCT05654623) - POSITIVE</h4>
                            <p class="detail-text">
                                <strong>Design:</strong> Global randomized Phase 3, open-label with BICR
                                <br><strong>Population:</strong> ER+/HER2- MBC after progression on CDK4/6i + ET
                                <br><strong>n=624:</strong> 26 countries, stratified by ESR1 mutation status (43% ESR1-mut)
                                <br><strong>Arms:</strong> Vepdegestrant 200mg QD vs Fulvestrant 500mg IM
                                <br><strong>Co-Primary Endpoints:</strong> PFS in ESR1-mut and ITT populations
                            </p>
                            
                            <div class="highlight-box mt-3">
                                <h5 class="font-semibold">Primary Results - ESR1-Mutant Population:</h5>
                                <p class="detail-text">
                                    • Median PFS: 5.0 vs 2.1 months (HR 0.57, 95% CI: 0.42-0.77, p<0.001)
                                    <br>• 6-month PFS rate: 45.2% vs 22.7%
                                    <br>• CBR: 42.1% vs 20.2% (OR 2.88, p<0.001)
                                    <br>• ORR: 18.6% vs 4.0% (OR 5.45, p=0.001)
                                </p>
                            </div>
                            
                            <p class="detail-text mt-2">
                                <strong>ITT Population:</strong> Median PFS 3.7 vs 3.6 months (HR 0.83, p=0.07) - not significant
                                <br><strong>Safety:</strong> Well-tolerated, 3% discontinuation for AEs
                                <br><strong>Status:</strong> Met primary endpoint, data presented ASCO 2025, published NEJM
                            </p>
                            <div class="reference-list">
                                <a href="https://clinicaltrials.gov/ct2/show/NCT05654623" target="_blank" class="link-btn">View on ClinicalTrials.gov →</a>
                            </div>
                        </div>
                    </div>

                    <!-- Ongoing/Future Trials -->
                    <div class="timeline-item">
                        <div class="timeline-dot" style="background: #084298;"></div>
                        <div class="timeline-date">2024-Ongoing</div>
                        <div class="timeline-content">
                            <h4 class="font-semibold">Phase 3 VERITAC-3 (NCT05909397) - RECRUITING</h4>
                            <p class="detail-text">
                                <strong>Design:</strong> Open-label, randomized Phase 3
                                <br><strong>Setting:</strong> First-line ER+/HER2- MBC (no prior systemic therapy for advanced disease)
                                <br><strong>n=~500 planned:</strong> Global enrollment including China
                                <br><strong>Arms:</strong> 
                                <br>• Vepdegestrant 200mg + Palbociclib 125mg (3 weeks on/1 off)
                                <br>• Letrozole 2.5mg + Palbociclib 125mg (control)
                                <br><strong>Primary Endpoint:</strong> PFS by central review
                            </p>
                            <p class="detail-text mt-2">
                                <strong>Rationale:</strong> Test if PROTAC ER degrader superior to AI in first-line with CDK4/6i
                                <br><strong>Status:</strong> Actively recruiting
                                <br><strong>Note:</strong> Originally planned additional first-line trial canceled in May 2025
                            </p>
                            <div class="reference-list">
                                <a href="https://clinicaltrials.gov/ct2/show/NCT05909397" target="_blank" class="link-btn">View on ClinicalTrials.gov →</a>
                            </div>
                        </div>
                    </div>

                    <!-- Canceled/Future Studies -->
                    <div class="timeline-item">
                        <div class="timeline-dot" style="background: #dc3545;"></div>
                        <div class="timeline-date">2025</div>
                        <div class="timeline-content">
                            <h4 class="font-semibold">Canceled/Deferred Trials (May 2025 Restructuring)</h4>
                            <p class="detail-text">
                                <strong>Canceled Studies:</strong>
                                <br>• Additional first-line combination Phase 3
                                <br>• Second-line combination expansion
                                <br>• Reason: Capital preservation, focus on core indication
                                <br>• Impact: Limited near-term expansion but preserves cash
                            </p>
                            <p class="detail-text mt-2">
                                <strong>Future Potential Studies:</strong>
                                <br>• TACTIVE-E: Vepdegestrant + Everolimus (mTOR inhibitor) - Phase 1b initiated
                                <br>• Neoadjuvant early breast cancer study - planned
                                <br>• Adjuvant setting - long-term opportunity
                            </p>
                        </div>
                    </div>
                </div>

                <!-- Comprehensive Trial Comparison Table -->
                <div class="subsection-title">Complete Trial Data Summary</div>
                <table class="trial-table">
                    <thead>
                        <tr>
                            <th>Trial</th>
                            <th>Phase</th>
                            <th>N</th>
                            <th>Population</th>
                            <th>Primary Endpoint</th>
                            <th>Key Results</th>
                            <th>Status</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>ARV-471-mBC-101</td>
                            <td>1</td>
                            <td>60</td>
                            <td>Heavily pretreated</td>
                            <td>MTD, Safety</td>
                            <td>No DLTs, CBR 40%, RP2D 200mg</td>
                            <td><span class="status-badge status-completed">Completed</span></td>
                        </tr>
                        <tr>
                            <td>VERITAC Expansion</td>
                            <td>2</td>
                            <td>~100</td>
                            <td>Post-CDK4/6i</td>
                            <td>ORR, CBR</td>
                            <td>CBR 50% ESR1-mut, PFS 5.5mo</td>
                            <td><span class="status-badge status-completed">Completed</span></td>
                        </tr>
                        <tr>
                            <td>Palbociclib Combo</td>
                            <td>1b</td>
                            <td>~50</td>
                            <td>Various lines</td>
                            <td>Safety, PK</td>
                            <td>PFS 13.9mo, PK interaction</td>
                            <td><span class="status-badge status-completed">Completed</span></td>
                        </tr>
                        <tr>
                            <td>China Bridging</td>
                            <td>1b</td>
                            <td>9</td>
                            <td>Chinese pts</td>
                            <td>PK, Safety</td>
                            <td>Comparable to global</td>
                            <td><span class="status-badge status-completed">Completed</span></td>
                        </tr>
                        <tr>
                            <td>Japan PK</td>
                            <td>1</td>
                            <td>Small</td>
                            <td>Japanese pts</td>
                            <td>PK, Safety</td>
                            <td>No new signals</td>
                            <td><span class="status-badge status-completed">Completed</span></td>
                        </tr>
                        <tr style="background: #f0f7f6;">
                            <td><strong>VERITAC-2</strong></td>
                            <td><strong>3</strong></td>
                            <td><strong>624</strong></td>
                            <td><strong>Post-CDK4/6i</strong></td>
                            <td><strong>PFS (ESR1-mut)</strong></td>
                            <td><strong>HR 0.57, p<0.001 ✓</strong></td>
                            <td><span class="status-badge status-completed">POSITIVE</span></td>
                        </tr>
                        <tr>
                            <td>VERITAC-3</td>
                            <td>3</td>
                            <td>500</td>
                            <td>1st-line MBC</td>
                            <td>PFS</td>
                            <td>Pending</td>
                            <td><span class="status-badge status-recruiting">Recruiting</span></td>
                        </tr>
                        <tr>
                            <td>TACTIVE-E</td>
                            <td>1b</td>
                            <td>TBD</td>
                            <td>With everolimus</td>
                            <td>Safety</td>
                            <td>Initiated</td>
                            <td><span class="status-badge status-recruiting">Starting</span></td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <!-- Complete Trial Analysis Tab -->
<div id="trials" class="tab-content">
    <div class="section-title">8. Complete Clinical Trial Portfolio Analysis - Vepdegestrant (ARV-471)</div>

    <!-- Critical Diligence Framework -->
    <div class="highlight-box mb-6">
        <h4 class="font-semibold mb-2">Investment Committee Trial Assessment Framework</h4>
        <p class="detail-text">
            Comprehensive analysis addressing all Phase 1-3 diligence requirements per investment committee standards: DLT windows, AE/PRO capture methodology, control arm justification, placebo anchoring, regional bias mitigation, and regulatory alignment.
        </p>
    </div>

    <!-- Trial Timeline -->
    <div class="timeline-container">
        <div class="timeline-line"></div>
        
        <!-- Phase 1/2 First-in-Human -->
        <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-date">2019-2021</div>
            <div class="timeline-content">
                <h4 class="font-semibold">Phase 1/2 First-in-Human (ARV-471-mBC-101 / NCT04072952)</h4>
                
                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Trial Design & Control Strategy</h5>
                    <p class="detail-text">
                        <strong>Blinding/Control:</strong> Open-label, single-arm dose escalation (3+3 design) with expansion cohorts. No blinding, no concurrent control → purely signal-finding.
                        <br><strong>Design:</strong> Part A (dose escalation monotherapy), Part B (expansion monotherapy), Part C (combination with palbociclib)
                        <br><strong>Comparator Frame:</strong> No placebo anchor or concurrent control. Treatment effect inferred against historical benchmarks only (post-CDK4/6i endocrine therapy: median PFS ~2-3 months, ORR ~5-10%).
                        <br><strong>Investment Risk:</strong> "It's not going to be blinded... we just want to see what that treatment effect might be" - uncontrolled design limits interpretability.
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">DLT/MTD/RP2D Determination</h5>
                    <p class="detail-text">
                        <strong>DLT Window:</strong> Cycle 1 (28 days) - explicitly defined in Japanese protocol & SAP as "first-cycle DLTs"
                        <br><strong>DLT Criteria:</strong> CTCAE v5.0 grading. Protocol section 6.5.1 specifies dose interruption/reduction rules
                        <br><strong>Dose Escalation:</strong> Classical 3+3 design from 30mg to 700mg QD
                        <br><strong>Key Finding:</strong> NO DLTs observed up to 700mg/day - MTD not reached
                        <br><strong>RP2D/RP3D Selection:</strong> 200mg QD selected based on:
                        <br>• PK/PD modeling (89% ER degradation achieved)
                        <br>• QTc safety modeling (200mg predicted ΔQTcF ~6.8ms vs 500mg ~14.7ms)
                        <br>• Overall benefit-risk assessment
                        <br><strong>Note:</strong> Some expansion evaluated 500mg QD but 200mg chosen for Phase 3
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">AE/PRO Capture Methodology</h5>
                    <p class="detail-text">
                        <strong>AE Collection:</strong> Investigator-elicited and graded by CTCAE v5.0
                        <br>• TEAEs/SAEs collected on scheduled visits
                        <br>• Labs and ECG monitoring (explicit QTc risk management)
                        <br>• Standard oncology visit cadence
                        <br><strong>PRO Tools:</strong> NOT SPECIFIED in Phase 1 - relies entirely on investigator assessment
                        <br><strong>Critical Risk:</strong> Without PROs, subjective toxicities (fatigue, nausea) likely under-reported
                        <br><strong>Investment Quote:</strong> "You'll get a bunch of zeros in terms of adverse event reporting... especially if it's a patient reported outcome"
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Regional/Site Effects & Bias Risk</h5>
                    <p class="detail-text">
                        <strong>Geographic Distribution:</strong> Global enrollment across multiple regions
                        <br><strong>Later Bridging:</strong> Dedicated Japan (NCT05463952) and China (NCT05732428) PK/safety studies
                        <br><strong>Cultural Bias Risk:</strong> Open-label + investigator-elicited AEs + mixed site cultures = systematic bias toward favorable benefit-risk
                        <br><strong>Specific Concern:</strong> "Respect factor" in Asian sites leads to AE under-reporting
                        <br><strong>Mitigation:</strong> Limited - no central review, no PRO tools, entirely investigator-dependent
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Key Results - Parts A/B Monotherapy</h5>
                    <p class="detail-text">
                        <strong>Population:</strong> Heavily pretreated ER+/HER2- MBC (median 4 prior lines, all had CDK4/6i)
                        <br><strong>n=60:</strong> 47 evaluable for efficacy
                        <br><strong>Efficacy Signals:</strong>
                        <br>• CBR: 40% (19/47 patients) overall, ~36-40% across cohorts
                        <br>• ORR: ~6-9% in heavily pretreated (3 PRs in 38 with measurable disease)
                        <br>• Duration: 2 patients remained on treatment >18 months
                        <br><strong>Safety Profile:</strong>
                        <br>• Common TRAEs: nausea (29%), fatigue (20%), vomiting (10%)
                        <br>• Mostly Grade 1-2 events
                        <br>• Only 1 patient (<2%) discontinued due to TRAE
                        <br>• ER degradation: 89% at 200mg dose
                    </p>
                </div>

                <div class="risk-item mt-3">
                    <div class="risk-indicator risk-high"></div>
                    <div>
                        <strong>Investment Risk:</strong> Single-arm, open-label, no placebo anchor means true treatment effect cannot be determined. Historical comparisons unreliable given patient selection differences. Investigator-only AE assessment without PROs systematically under-reports toxicity.
                    </div>
                </div>

                <div class="reference-list">
                    Sources: ClinicalTrials.gov NCT04072952 | Cancer.gov | Arvinas Medical Affairs | Protocol Section 6.5.1
                </div>
            </div>
        </div>

        <!-- Phase 1b Combination with Palbociclib -->
        <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-date">2021-2024</div>
            <div class="timeline-content">
                <h4 class="font-semibold">Phase 1b Combination - Part C (Vepdegestrant + Palbociclib)</h4>
                
                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Combination Cohort Design</h5>
                    <p class="detail-text">
                        <strong>Design:</strong> Open-label expansion, no control arm
                        <br><strong>Dose:</strong> Vepdegestrant 200mg QD + Palbociclib 125mg (3 weeks on/1 off)
                        <br><strong>Cohorts:</strong> 
                        <br>• CDK4/6i-naïve patients
                        <br>• CDK4/6i-pretreated patients
                        <br><strong>Sample Size Logic:</strong> Not powered for confirmatory efficacy - aimed at RDE/PK and preliminary activity
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">PK Interaction & Dose Optimization</h5>
                    <p class="detail-text">
                        <strong>Critical Finding:</strong> Vepdegestrant increased palbociclib exposure by 46-58% vs historical
                        <br><strong>DLT Window:</strong> Cycle 1 (28 days)
                        <br><strong>DLT Assessment:</strong> CTCAE v5.0
                        <br><strong>Dose Modification:</strong> Required optimization strategy for Phase 3 based on PK interaction
                        <br><strong>Impact:</strong> Informs dosing for VERITAC-3 first-line combination trial
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Efficacy & Durability Results</h5>
                    <p class="detail-text">
                        <strong>Updated PFS:</strong> 13.9 months (95% CI: 8.1-NR) at recommended Phase 3 combo dose
                        <br><strong>CBR:</strong> ~63% in interim analyses
                        <br><strong>ORR:</strong> 
                        <br>• Overall: ~42%
                        <br>• CDK4/6i-naïve subset: ~59% (notably higher)
                        <br><strong>Durability:</strong> Follow-up ongoing for mature DoR
                        <br><strong>Combination Viability:</strong> Deemed feasible with dose optimization
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Biomarker Strategy & Enrichment</h5>
                    <p class="detail-text">
                        <strong>Approach:</strong> Mechanism-based, NOT biomarker-selected
                        <br><strong>ESR1 Testing:</strong> Not required for enrollment in Part C
                        <br><strong>No Companion Dx:</strong> Used in combination expansion
                        <br><strong>Investment Risk:</strong> "Problem is fundamentally the validation of the biomarker... they need to have a control arm" - without control, biomarker effects cannot be validated
                        <br><strong>Note:</strong> ESR1 becomes central selection factor in Phase 3 VERITAC-2
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">AE/PRO Capture & Regional Consistency</h5>
                    <p class="detail-text">
                        <strong>AEs:</strong> Investigator-reported CTCAE v5.0, standard oncology cadence
                        <br><strong>PRO Tools:</strong> NOT SPECIFIED in Phase 1b combination
                        <br><strong>Regional Mix:</strong> Global multi-site enrollment
                        <br><strong>Consistency Check:</strong> No single-country dominance reported
                        <br><strong>Note:</strong> PK interaction universal, not region-specific
                    </p>
                </div>

                <div class="risk-item mt-3">
                    <div class="risk-indicator risk-medium"></div>
                    <div>
                        <strong>Investment Risk:</strong> Uncontrolled combination signals require careful interpretation. PK interaction necessitates dose optimization. Without validated biomarker gate, signals "won't inform" beyond feasibility unless anchored against control (which VERITAC-3 provides).
                    </div>
                </div>

                <div class="reference-list">
                    Note: First-line combination Phase 3 (VERITAC-3 precursor) later canceled in May 2025 restructuring
                </div>
            </div>
        </div>

        <!-- Phase 2 VERITAC Expansion -->
        <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-date">2021-2023</div>
            <div class="timeline-content">
                <h4 class="font-semibold">Phase 2 VERITAC Single-Arm Expansion</h4>
                
                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Trial Design & Comparator Frame</h5>
                    <p class="detail-text">
                        <strong>Design:</strong> Single-arm, open-label expansion at 200mg QD
                        <br><strong>Blinding/Control:</strong> None - purely signal-seeking
                        <br><strong>Comparator:</strong> Historical controls only (post-CDK4/6i endocrine-resistant benchmarks)
                        <br><strong>Placebo Anchor:</strong> NONE - descriptive vs SoC benchmarks only
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Population & Biomarker Enrichment</h5>
                    <p class="detail-text">
                        <strong>Population:</strong> ER+/HER2- MBC after CDK4/6i progression
                        <br><strong>n=~100:</strong> Enriched for ESR1 mutations
                        <br><strong>Stratification:</strong> Included both ESR1-mutant and wild-type
                        <br><strong>Primary Endpoints:</strong> ORR, CBR, safety
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Key Efficacy Results by Biomarker</h5>
                    <p class="detail-text">
                        <strong>Overall Population:</strong>
                        <br>• CBR: ~38%
                        <br>• ORR: ~6% (heavily pretreated)
                        <br>• Median PFS: Not specified for all-comers
                        
                        <br><br><strong>ESR1-Mutant Subset (Key Finding):</strong>
                        <br>• CBR: ~50% (substantially higher)
                        <br>• Median PFS: ~5.5 months
                        <br>• Some patients ≥48 weeks on treatment
                        
                        <br><br><strong>Significance:</strong> Confirmed activity enriched in ESR1-mutant tumors → justifies Phase 3 biomarker strategy
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">AE/PRO Reporting & Regional Effects</h5>
                    <p class="detail-text">
                        <strong>AEs:</strong> Investigator-reported only
                        <br><strong>PRO Instruments:</strong> Not publicly listed
                        <br><strong>Regional Enrollment:</strong> Global
                        <br><strong>Recommended Analysis:</strong> Per-region AE/efficacy slicing at final CSR to mitigate cultural under-reporting
                        <br><strong>Tolerability:</strong> Favorable profile maintained from Phase 1
                    </p>
                </div>

                <div class="risk-item mt-3">
                    <div class="risk-indicator risk-medium"></div>
                    <div>
                        <strong>Investment Assessment:</strong> Single-arm design provides directional signal only. ESR1 enrichment hypothesis generated but requires controlled study for validation. Sets stage for Phase 3 design.
                    </div>
                </div>
            </div>
        </div>

        <!-- Regional Bridging Studies -->
        <div class="timeline-item">
            <div class="timeline-dot"></div>
            <div class="timeline-date">2023-2024</div>
            <div class="timeline-content">
                <h4 class="font-semibold">Regional PK/Safety Bridging Studies - Critical for Global Filing</h4>
                
                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Japan Phase 1 Study (NCT05463952 / C4891016)</h5>
                    <p class="detail-text">
                        <strong>Design:</strong> Open-label, single-arm at 200mg QD
                        <br><strong>Primary:</strong> PK parameters and safety in Japanese patients
                        <br><strong>Key Documents:</strong>
                        <br>• Protocol explicitly defines Cycle 1 (28 days) DLT window
                        <br>• SAP confirms first-cycle DLT estimand
                        <br>• CSR synopsis published showing tolerability
                        <br><strong>PK Results:</strong> Confirmed exposure matching to Western populations
                        <br><strong>Safety:</strong> No new signals, supports global program inclusion
                        <br><strong>Publication:</strong> Peer-reviewed paper 2024/2025
                    </p>
                </div>
                
                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">China PK/Safety Study (NCT05732428)</h5>
                    <p class="detail-text">
                        <strong>Design:</strong> Mirrors Japan study at 200mg QD
                        <br><strong>n=9:</strong> Small bridging cohort for NMPA requirements
                        <br><strong>Results:</strong> Not yet widely posted but forms basis for China inclusion in global trials
                        <br><strong>Critical Risk:</strong> Chinese studies show "bunch of zeros" in AE reporting
                        <br><strong>Investment Warning:</strong> "It's even worse when it's from China... AEs are underreported"
                        <br><strong>Mitigation:</strong> Don't rely on China safety data alone - require global comparisons
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">US Re-Run Requirements Assessment</h5>
                    <p class="detail-text">
                        <strong>Arvinas Approach:</strong> Did NOT re-run Phase 1 in US after Asia data
                        <br><strong>Rationale:</strong> FIH was already global with US sites included
                        <br><strong>GSK Precedent:</strong> "GSK has policy... they redo phase one data in US... because it's notoriously inflated"
                        <br><strong>Key Difference:</strong> Phase 3 VERITAC-2 was global, randomized, with BICR - addresses "China-only inflation" concern
                        <br><strong>Investment Recommendation:</strong> Accept global data but require US/EU subset analysis
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Mitigations for AE/PRO Under-Reporting</h5>
                    <p class="detail-text">
                        <strong>Required for Diligence:</strong>
                        <br>• Standardized AE-elicitation training across sites
                        <br>• Validated translations for PRO instruments
                        <br>• Electronic PRO (ePRO) capture to reduce site influence
                        <br>• QC checks on "all-zero" AE patterns
                        <br>• Central review (BICR) for imaging endpoints
                        <br><strong>Implementation:</strong> BICR already in VERITAC-2, planned for VERITAC-3
                    </p>
                </div>

                <div class="risk-item mt-3">
                    <div class="risk-indicator risk-high"></div>
                    <div>
                        <strong>Critical Due Diligence:</strong> Request region-stratified safety and efficacy data. Chinese/Japanese cohorts likely show lower AE rates and higher response rates. Weight US/EU data more heavily in benefit-risk assessment.
                    </div>
                </div>
            </div>
        </div>

        <!-- Phase 3 VERITAC-2 POSITIVE -->
        <div class="timeline-item">
            <div class="timeline-dot" style="background: #28a745;"></div>
            <div class="timeline-date">2023-2025</div>
            <div class="timeline-content">
                <h4 class="font-semibold">🏆 Phase 3 VERITAC-2 (NCT05654623) - POSITIVE PIVOTAL TRIAL</h4>
                
                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Trial Design & Control Strategy</h5>
                    <p class="detail-text">
                        <strong>Design:</strong> Open-label, randomized 1:1, global multicenter
                        <br><strong>Control Arm Justification:</strong> Fulvestrant is widely used active SoC in post-CDK4/6i setting
                        <br><strong>Why Acceptable:</strong> Head-to-head directly measures treatment effect (avoids "squishy SoC" historical comparisons)
                        <br><strong>Blinding:</strong> Open-label BUT uses BICR for primary endpoint (mitigates bias)
                        <br><strong>Population:</strong> ER+/HER2- MBC after progression on CDK4/6i + ET
                        <br><strong>n=624:</strong> 26 countries, stratified by ESR1 mutation status (43% ESR1-mut)
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Sample Size & Power Assumptions</h5>
                    <p class="detail-text">
                        <strong>Sample Size:</strong> n=624 allows co-primary PFS testing in ESR1-mut and ITT
                        <br><strong>Power Calculation:</strong> Designed for adequate power to detect clinically meaningful difference
                        <br><strong>Co-Primary Strategy:</strong> PFS by BICR in both ESR1-mutant and ITT populations
                        <br><strong>Alpha Split:</strong> Not publicly disclosed in registry papers
                        <br><strong>Event-Driven:</strong> Analysis at pre-specified PFS events
                        <br><strong>Investment Note:</strong> "They basically put a finger in the wind to come up with sample size" - but this was well-powered
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Primary Endpoint Strategy & BICR</h5>
                    <p class="detail-text">
                        <strong>Co-Primary Endpoints:</strong> PFS by BICR in ESR1-mut AND ITT populations
                        <br><strong>BICR Importance:</strong> Reduces open-label bias - "provides objectivity comparable to placebo-anchored assessments"
                        <br><strong>Key Secondaries:</strong> OS, ORR, CBR, DoR, safety, QoL
                        <br><strong>Hierarchy:</strong> Not publicly detailed
                        <br><strong>Interim Analyses:</strong> Plan not publicly disclosed
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">POSITIVE PRIMARY RESULTS - ESR1-Mutant Population</h5>
                    <div class="highlight-box">
                        <p class="detail-text">
                            <strong>Median PFS:</strong> 5.0 vs 2.1 months (HR 0.57, 95% CI: 0.42-0.77, p<0.001)
                            <br><strong>6-month PFS Rate:</strong> 45.2% vs 22.7%
                            <br><strong>ORR:</strong> 18.6% vs 4.0% (OR 5.45, p=0.001)
                            <br><strong>CBR:</strong> 42.1% vs 20.2% (OR 2.88, p<0.001)
                            <br><strong>PRIMARY ENDPOINT MET</strong> - Statistically significant and clinically meaningful
                        </p>
                    </div>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">ITT Population Results</h5>
                    <p class="detail-text">
                        <strong>Median PFS:</strong> 3.7 vs 3.6 months (HR 0.83, 95% CI: 0.68-1.02, p=0.07)
                        <br><strong>Not Statistically Significant:</strong> Benefit concentrated in ESR1-mutant subset
                        <br><strong>Implication:</strong> Label will be restricted to ESR1-mutant population
                        <br><strong>OS Data:</strong> Immature with <25% events - follow-up ongoing
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Safety Profile & Tolerability</h5>
                    <p class="detail-text">
                        <strong>Discontinuation for AEs:</strong> Only 3% (excellent tolerability)
                        <br><strong>Grade ≥3 TEAEs:</strong> 23.4% vs 17.6% fulvestrant
                        <br><strong>Key Differentiator:</strong> Low GI toxicity (13.5% nausea) vs elacestrant (35%)
                        <br><strong>No Treatment-Related Deaths:</strong> Clean safety profile
                        <br><strong>Dose Intensity:</strong> >95% maintained (minimal reductions)
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">AE/PRO Elicitation & Regional Analysis</h5>
                    <p class="detail-text">
                        <strong>AEs:</strong> Investigator-reported CTCAE v5.0 through follow-up
                        <br><strong>PRO Instruments:</strong> Not itemized in public summaries (typical: EORTC/EQ-5D)
                        <br><strong>Flag for Diligence:</strong> Request full PRO schedule from CSR/protocol
                        <br><strong>Regional Mix:</strong> 26 countries including US, EU, Asia, LatAm
                        <br><strong>BICR Mitigation:</strong> Central imaging reduces regional variation
                        <br><strong>Recommended:</strong> Per-region PFS/AE/PRO slices during review
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Regulatory & PTRS Impact</h5>
                    <p class="detail-text">
                        <strong>NDA Status:</strong> ACCEPTED with Priority Review
                        <br><strong>PDUFA Date:</strong> Q1 2026
                        <br><strong>Fast Track:</strong> Granted February 2024
                        <br><strong>PTRS Lift:</strong> Positive Phase 3 dramatically increases probability of approval
                        <br><strong>Label Expectation:</strong> ESR1-mutant ER+/HER2- MBC after CDK4/6i
                        <br><strong>Publication:</strong> NEJM publication adds credibility
                    </p>
                </div>

                <div class="risk-item mt-3">
                    <div class="risk-indicator risk-low"></div>
                    <div>
                        <strong>Investment Assessment:</strong> Well-executed pivotal trial with clear positive results in biomarker-defined population. BICR mitigates open-label bias. Active control provides direct comparison. Regulatory approval highly likely.
                    </div>
                </div>

                <div class="reference-list">
                    Sources: ClinicalTrials.gov NCT05654623 | NEJM | ASCO 2025 | Pfizer Press Release
                </div>
            </div>
        </div>

        <!-- Phase 3 VERITAC-3 Ongoing -->
        <div class="timeline-item">
            <div class="timeline-dot" style="background: #084298;"></div>
            <div class="timeline-date">2024-Ongoing</div>
            <div class="timeline-content">
                <h4 class="font-semibold">Phase 3 VERITAC-3 - First-Line Combination (NCT05909397) - RECRUITING</h4>
                
                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Trial Design & Control Justification</h5>
                    <p class="detail-text">
                        <strong>Design:</strong> Open-label, randomized, global Phase 3
                        <br><strong>Arms:</strong>
                        <br>• Vepdegestrant 200mg + Palbociclib 125mg
                        <br>• Letrozole 2.5mg + Palbociclib 125mg (control)
                        <br><strong>Control Justification:</strong> First-line SoC is AI + CDK4/6i
                        <br><strong>Why Acceptable:</strong> Replacing AI with vepdegestrant while holding palbociclib constant directly tests PROTAC superiority
                        <br><strong>Investment Note:</strong> "SoC add-on logic the agencies expect"
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Sample Size & Statistical Plan</h5>
                    <p class="detail-text">
                        <strong>Planned N:</strong> ~500 patients
                        <br><strong>Power Assumptions:</strong> Event-driven PFS by central review
                        <br><strong>Target HR:</strong> Likely ~0.70-0.75 for clinically meaningful difference
                        <br><strong>Alpha/Power:</strong> Not publicly disclosed
                        <br><strong>Challenge:</strong> Must beat AI+palbociclib (median PFS ~25 months in PALOMA-2)
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Primary Endpoint & BICR Strategy</h5>
                    <p class="detail-text">
                        <strong>Primary:</strong> PFS by CENTRAL REVIEW (BICR-equivalent)
                        <br><strong>Importance:</strong> Mitigates open-label bias
                        <br><strong>Secondaries:</strong> OS, ORR, DoR, safety, QoL
                        <br><strong>Interims/Futility:</strong> Not publicly disclosed
                        <br><strong>Crossover Policy:</strong> Not stated - critical for OS power
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">PK Interaction Management</h5>
                    <p class="detail-text">
                        <strong>Critical Issue:</strong> Vepdegestrant increases palbociclib exposure by 46-58%
                        <br><strong>Dose Strategy:</strong> Based on Phase 1b optimization
                        <br><strong>Monitoring:</strong> Enhanced hematologic AE surveillance required
                        <br><strong>Risk:</strong> Overlapping toxicities could limit tolerability advantage
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">PTRS Considerations & SME Triangulation</h5>
                    <p class="detail-text">
                        <strong>Key Question:</strong> Can PROTAC beat AI when both combined with CDK4/6i?
                        <br><strong>Benchmarks Needed:</strong>
                        <br>• PALOMA-2 (letrozole+palbociclib): median PFS ~25 months
                        <br>• SERENA-6 (camizestrant combinations)
                        <br>• Other SERD/PROTAC first-line data
                        <br><strong>SME Assessment:</strong> Need absolute PFS gain >3-6 months to be commercially viable
                        <br><strong>Investment Quote:</strong> "We have an AI tool that generates PTRSs... frequently wrong... that's why the subject matter expert needed"
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Regional Strategy & China Inclusion</h5>
                    <p class="detail-text">
                        <strong>Global Enrollment:</strong> Including China sites
                        <br><strong>Purpose:</strong> Enables NMPA submission
                        <br><strong>Risk Mitigation:</strong>
                        <br>• Central review for primary endpoint
                        <br>• Per-region AE/PRO compliance monitoring
                        <br>• Site-level quality checks
                        <br><strong>Investment Action:</strong> Request per-region efficacy/safety slices
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Strategic Importance & Timeline</h5>
                    <p class="detail-text">
                        <strong>Rationale:</strong> Test if PROTAC ER degrader superior to AI in first-line
                        <br><strong>Status:</strong> Actively recruiting
                        <br><strong>Note:</strong> Additional first-line trial canceled in May 2025 restructuring
                        <br><strong>Timeline:</strong> Results expected 2027-2028
                        <br><strong>Commercial Impact:</strong> Success would dramatically expand market opportunity
                    </p>
                </div>

                <div class="risk-item mt-3">
                    <div class="risk-indicator risk-medium"></div>
                    <div>
                        <strong>Investment Assessment:</strong> High-risk/high-reward trial. Must demonstrate superiority over excellent SoC. PK interaction adds complexity. Success would be transformative but probability moderate.
                    </div>
                </div>
            </div>
        </div>

        <!-- Canceled/Future Studies -->
        <div class="timeline-item">
            <div class="timeline-dot" style="background: #dc3545;"></div>
            <div class="timeline-date">2025</div>
            <div class="timeline-content">
                <h4 class="font-semibold">Canceled/Deferred Trials - May 2025 Restructuring</h4>
                
                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Portfolio Prioritization Decision</h5>
                    <p class="detail-text">
                        <strong>Canceled Studies:</strong>
                        <br>• Additional first-line combination Phase 3
                        <br>• Second-line combination expansion studies
                        <br><strong>Reason:</strong> Capital preservation, focus on core ESR1-mutant indication
                        <br><strong>Workforce Impact:</strong> 33% reduction announced
                        <br><strong>Financial Impact:</strong> Extends cash runway to 2H 2028
                    </p>
                </div>

                <div class="data-card mt-3">
                    <h5 class="font-semibold text-green-700 mb-2">Future Development Opportunities</h5>
                    <p class="detail-text">
                        <strong>TACTIVE-E:</strong> Vepdegestrant + Everolimus (mTOR inhibitor)
                        <br>• Phase 1b initiated for PI3K/AKT-mediated resistance
                        <br>• Could open ESR1-mut + PI3K-activated population
                        
                        <br><br><strong>Neoadjuvant Setting:</strong> Early breast cancer study planned
                        <br>• Test if profound ER degradation shrinks tumors pre-surgery
                        <br>• Positions for eventual adjuvant use
                        
                        <br><br><strong>Adjuvant Market:</strong> Long-term opportunity
                        <br>• Hundreds of thousands of patients globally
                        <br>• Requires demonstrating relapse prevention
                    </p>
                </div>

                <div class="risk-item mt-3">
                    <div class="risk-indicator risk-high"></div>
                    <div>
                        <strong>Investment Signal:</strong> Trial cancellations indicate capital constraints and strategic focus. Company prioritizing highest-probability path to approval rather than broad development.
                    </div>
                </div>
            </div>
        </div>
    </div>

    <!-- Comprehensive Trial Summary Table -->
    <div class="subsection-title">Complete Trial Portfolio Summary</div>
    <table class="trial-table">
        <thead>
            <tr>
                <th>Trial</th>
                <th>Phase</th>
                <th>N</th>
                <th>Control</th>
                <th>Blinding</th>
                <th>Primary</th>
                <th>Key Issues</th>
                <th>Investment Risk</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>ARV-471-mBC-101</td>
                <td>1/2</td>
                <td>60</td>
                <td>None</td>
                <td>Open</td>
                <td>MTD/Safety</td>
                <td>No PROs, no control</td>
                <td><span class="text-yellow-600">Medium</span></td>
            </tr>
            <tr>
                <td>Part C Combo</td>
                <td>1b</td>
                <td>~50</td>
                <td>None</td>
                <td>Open</td>
                <td>Safety/PK</td>
                <td>PK interaction 46-58%</td>
                <td><span class="text-yellow-600">Medium</span></td>
            </tr>
            <tr>
                <td>VERITAC Expansion</td>
                <td>2</td>
                <td>~100</td>
                <td>None</td>
                <td>Open</td>
                <td>ORR/CBR</td>
                <td>ESR1 signal found</td>
                <td><span class="text-green-600">Low</span></td>
            </tr>
            <tr>
                <td>China Bridge</td>
                <td>1</td>
                <td>9</td>
                <td>None</td>
                <td>Open</td>
                <td>PK/Safety</td>
                <td>AE under-reporting</td>
                <td><span class="text-yellow-600">Medium</span></td>
            </tr>
            <tr>
                <td>Japan Bridge</td>
                <td>1</td>
                <td>Small</td>
                <td>None</td>
                <td>Open</td>
                <td>PK/Safety</td>
                <td>Cultural bias</td>
                <td><span class="text-yellow-600">Medium</span></td>
            </tr>
            <tr style="background: #d4f4ec;">
                <td><strong>VERITAC-2</strong></td>
                <td><strong>3</strong></td>
                <td><strong>624</strong></td>
                <td><strong>Active</strong></td>
                <td><strong>Open+BICR</strong></td>
                <td><strong>PFS (ESR1)</strong></td>
                <td><strong>POSITIVE - HR 0.57</strong></td>
                <td><span class="text-green-600"><strong>Low</strong></span></td>
            </tr>
            <tr>
                <td>VERITAC-3</td>
                <td>3</td>
                <td>500</td>
                <td>Active</td>
                <td>Open+CR</td>
                <td>PFS</td>
                <td>Must beat AI+CDK4/6i</td>
                <td><span class="text-yellow-600">Medium</span></td>
            </tr>
            <tr>
                <td>TACTIVE-E</td>
                <td>1b</td>
                <td>TBD</td>
                <td>None</td>
                <td>Open</td>
                <td>Safety</td>
                <td>Early stage combo</td>
                <td><span class="text-red-600">High</span></td>
            </tr>
        </tbody>
    </table>

    <!-- Critical Diligence Actions -->
    <div class="highlight-box mt-6">
        <h4 class="font-semibold mb-3">Critical Diligence Actions Required</h4>
        <p class="detail-text">
            <strong>1. Protocol/SAP Documents Needed:</strong>
            <br>• VERITAC-2: Alpha split for co-primary PFS, stratification factors, interim/futility rules
            <br>• VERITAC-3: Central review specifications, palbociclib exposure management
            <br>• Full DLT definitions from original ARV-471-mBC-101 protocol
            
            <br><br><strong>2. Regional Analysis Requirements:</strong>
            <br>• Per-region AE/PRO compliance reports
            <br>• PFS by geographic region (especially Asia vs US/EU)
            <br>• Site-level quality flags
            
            <br><br><strong>3. Biomarker Validation:</strong>
            <br>• ESR1 companion diagnostic status and approval timeline
            <br>• Testing availability and reimbursement strategy
            
            <br><br><strong>4. Safety Deep Dive:</strong>
            <br>• QTc concentration-effect modeling details
            <br>• Drug-drug interaction management protocols
            <br>• P-glycoprotein substrate interaction implications
        </p>
    </div>

    <!-- Investment Committee Summary -->
    <div class="highlight-box mt-6">
        <h4 class="font-semibold mb-3">Investment Committee Clinical Assessment - Vepdegestrant</h4>
        <p class="detail-text">
            <strong>Program Maturity:</strong> Advanced - positive Phase 3, NDA accepted with Priority Review
            
            <br><br><strong>Key Strengths:</strong>
            <br>• POSITIVE Phase 3 in ESR1-mutant population (HR 0.57, p0.001)
            <br>• First successful PROTAC validates platform technology
            <br>• Superior tolerability vs elacestrant (13.5% vs 35% nausea)
            <br>• NDA accepted, PDUFA Q1 2026 - de-risked regulatory path
            <br>• Strong IP protection to mid-2030s
            
            <br><br><strong>Critical Weaknesses:</strong>
            <br>• Limited to ESR1-mutant subset (~40% of 2L patients)
            <br>• No benefit in ITT population (HR 0.83, p=0.07)
            <br>• Company restructuring signals financial stress
            <br>• VERITAC-3 high-risk given excellent SoC comparator
            
            <br><br><strong>Investment Decision Factors:</strong>
            <br>• Near-term catalyst: FDA approval Q1 2026 (high probability)
            <br>• Arvinas trading below cash ($570M market cap vs $861M cash)
            <br>• Peak sales $1-2B potential in ESR1-mutant population
            <br>• Exit likely via Pfizer acquisition post-approval
            
            <br><br><strong>Risk-Adjusted Recommendation:</strong>
            <br>• Near-term: LOW RISK given positive Phase 3 and regulatory acceptance
            <br>• Long-term: MEDIUM RISK pending VERITAC-3 results and market uptake
            <br>• Structure: Consider royalty deal or convertible debt for downside protection
        </p>
    </div>
</div>
        </div>

        <!-- Investment Summary Section -->
        <div class="tab-container mt-6">
            <div class="section-title p-6">Investment Committee Summary</div>
            <div class="p-6">
                <div class="highlight-box">
                    <h3 class="text-xl font-bold mb-4 text-gray-900">Executive Investment Thesis</h3>
                    <p class="detail-text">
                        Vepdegestrant represents a compelling late-stage oncology investment with multi-dimensional strengths and manageable risks. As the first PROTAC to demonstrate Phase 3 success, it validates a novel mechanism while addressing clear unmet need in ESR1-mutant breast cancer.
                    </p>
                </div>

                <div class="metric-grid mt-6">
                    <div class="metric-card">
                        <div class="metric-label">Clinical Risk</div>
                        <div class="metric-value text-green-600">✓ Low</div>
                        <div class="metric-detail">Phase 3 met primary endpoint</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Regulatory Risk</div>
                        <div class="metric-value text-green-600">✓ Low</div>
                        <div class="metric-detail">NDA accepted, precedent exists</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Commercial Risk</div>
                        <div class="metric-value text-yellow-600">⚠ Medium</div>
                        <div class="metric-detail">Competition from elacestrant/camizestrant</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Financial Upside</div>
                        <div class="metric-value text-green-600">✓ High</div>
                        <div class="metric-detail">$1-2B peak sales potential</div>
                    </div>
                </div>

                <div class="data-card mt-6">
                    <h4 class="font-semibold mb-3">Key Investment Strengths</h4>
                    <ul class="space-y-2">
                        <li>✓ <strong>Strong Clinical Data:</strong> 43% risk reduction (HR 0.57) in ESR1-mutant population</li>
                        <li>✓ <strong>Superior Tolerability:</strong> 13.5% nausea vs 35% for elacestrant</li>
                        <li>✓ <strong>Novel Mechanism:</strong> First successful PROTAC validates platform</li>
                        <li>✓ <strong>Strong IP:</strong> Protection to mid-2030s with composition-of-matter patents</li>
                        <li>✓ <strong>Pfizer Partnership:</strong> 50/50 profit share with commercial expertise</li>
                        <li>✓ <strong>Valuation Disconnect:</strong> Arvinas trading below cash value despite positive data</li>
                    </ul>
                </div>

                <div class="data-card mt-4">
                    <h4 class="font-semibold mb-3">Key Investment Risks</h4>
                    <ul class="space-y-2">
                        <li>⚠ <strong>Limited Initial Market:</strong> ESR1-mutant subset only (~40% of 2L patients)</li>
                        <li>⚠ <strong>Competition:</strong> Elacestrant on market, camizestrant coming 2026-27</li>
                        <li>⚠ <strong>Expansion Trials Canceled:</strong> First-line opportunity delayed</li>
                        <li>⚠ <strong>Payer Scrutiny:</strong> High cost may face reimbursement challenges</li>
                        <li>⚠ <strong>Partnership Renegotiation:</strong> 50/50 split may be adjusted</li>
                    </ul>
                </div>

                <div class="data-card mt-4">
                    <h4 class="font-semibold mb-3">Financial Return Projections</h4>
                    <table class="trial-table">
                        <thead>
                            <tr>
                                <th>Scenario</th>
                                <th>Peak Sales</th>
                                <th>Arvinas Annual Profit</th>
                                <th>NPV @ 10%</th>
                                <th>IRR (5-year)</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Conservative</td>
                                <td>$1.0B</td>
                                <td>$350M</td>
                                <td>$1.5-2.0B</td>
                                <td>20-25%</td>
                            </tr>
                            <tr style="background: #f0f7f6;">
                                <td><strong>Base Case</strong></td>
                                <td><strong>$1.5B</strong></td>
                                <td><strong>$525M</strong></td>
                                <td><strong>$2.0-3.0B</strong></td>
                                <td><strong>25-30%</strong></td>
                            </tr>
                            <tr>
                                <td>Bull Case</td>
                                <td>$2.0B+</td>
                                <td>$700M+</td>
                                <td>$4.0-5.0B</td>
                                <td>35-40%</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="highlight-box mt-6">
                    <h4 class="font-semibold mb-2">Investment Recommendation</h4>
                    <p class="detail-text">
                        <strong>Rating: BUY with structured entry</strong>
                        <br><br>
                        Vepdegestrant offers compelling risk-adjusted returns given Arvinas' depressed valuation ($570M market cap vs $861M cash). The asset's rNPV of $2-3B far exceeds current enterprise value. Recommend structured investment via:
                        <br><br>
                        1. <strong>Convertible debt</strong> for downside protection
                        <br>2. <strong>Tranched investment</strong> with milestones (FDA approval)
                        <br>3. <strong>Royalty structure</strong> on Arvinas' 50% profit share
                        <br><br>
                        Exit likely via Pfizer acquisition (1-3 years) or public market re-rating upon commercial launch. Monitor camizestrant Phase 3 results and initial launch uptake versus elacestrant as key catalysts.
                    </p>
                </div>
            </div>
        </div>
    </div>

    <script>
        // Tab switching function
        function showTab(tabName) {
            document.querySelectorAll('.tab-content').forEach(tab => {
                tab.classList.remove('active');
            });
            
            document.querySelectorAll('.tab-btn').forEach(btn => {
                btn.classList.remove('active');
            });
            
            document.getElementById(tabName).classList.add('active');
            event.target.classList.add('active');
        }

        // Toggle expandable sections
        function toggleSection(header) {
            const content = header.nextElementSibling;
            const arrow = header.querySelector('span:last-child');
            
            if (content.classList.contains('active')) {
                content.classList.remove('active');
                arrow.textContent = '▶';
            } else {
                content.classList.add('active');
                arrow.textContent = '▼';
            }
        }

        // PFS Chart
        const pfsCtx = document.getElementById('pfsChart');
        if (pfsCtx) {
            new Chart(pfsCtx.getContext('2d'), {
                type: 'bar',
                data: {
                    labels: ['ESR1-mut Vepdegestrant', 'ESR1-mut Fulvestrant', 'All-comer Vepdegestrant', 'All-comer Fulvestrant'],
                    datasets: [{
                        label: 'Median PFS (months)',
                        data: [5.0, 2.1, 3.7, 3.6],
                        backgroundColor: ['#0a6b5e', '#e3f2f0', '#0a6b5e', '#e3f2f0'],
                        borderColor: '#0a6b5e',
                        borderWidth: 1
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: true,
                    plugins: {
                        title: {
                            display: true,
                            text: 'VERITAC-2: Progression-Free Survival Results'
                        },
                        legend: {
                            display: false
                        }
                    },
                    scales: {
                        y: {
                            beginAtZero: true,
                            title: {
                                display: true,
                                text: 'Months'
                            }
                        }
                    }
                }
            });
        }

        // Safety Comparison Chart
        const safetyCtx = document.getElementById('safetyComparisonChart');
        if (safetyCtx) {
            new Chart(safetyCtx.getContext('2d'), {
                type: 'horizontalBar',
                data: {
                    labels: ['Fatigue', 'ALT/AST Elevation', 'Nausea', 'Anemia', 'Neutropenia', 'Arthralgia'],
                    datasets: [{
                        label: 'Vepdegestrant (%)',
                        data: [27, 14, 13.5, 12, 12, 11],
                        backgroundColor: '#0a6b5e'
                    }, {
                        label: 'Fulvestrant (%)',
                        data: [16, 10, 9, 8, 5, 8],
                        backgroundColor: '#e3f2f0'
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: true,
                    plugins: {
                        title: {
                            display: true,
                            text: 'VERITAC-2: Adverse Event Comparison'
                        }
                    },
                    scales: {
                        x: {
                            beginAtZero: true,
                            max: 30,
                            title: {
                                display: true,
                                text: 'Incidence (%)'
                            }
                        }
                    }
                }
            });
        }
    </script>
</body>
</html>